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Molecular Mechanism of Synaptic Vesicle Degradation 
Patricia Sheehan 
 
Neurons rely on precise spatial and temporal control of neurotransmitter release to ensure proper 
communication. Neurotransmission occurs when synaptic vesicles in the presynaptic 
compartment fuse with the plasma membrane and release their contents into the synaptic cleft, 
where neurotransmitters bind to receptors on the postsynaptic neuron. Synaptic vesicle pools 
must maintain a functional repertoire of proteins in order to efficiently release neurotransmitter. 
Indeed, the accumulation of old or damaged proteins on synaptic vesicle membranes is linked to 
synaptic dysfunction and neurodegeneration. Despite the importance of synaptic vesicle protein 
turnover for neuronal health, the molecular mechanisms underlying this process are unknown. In 
this thesis, we present work that uncovers key components that regulate synaptic vesicle 
degradation.  Specifically, we identify a pathway that mediates the activity-dependent turnover 
of a subset of synaptic vesicle membrane proteins in mammalian neurons. This pathway requires 
the synaptic vesicle-associated GTPase Rab35, the ESCRT machinery, and synaptic vesicle 
protein ubiquitination. We further demonstrate that neuronal activity stimulates synaptic vesicle 
protein turnover by inducing Rab35 activation and binding to the ESCRT-0 component Hrs, 
which we have identified as a novel Rab35 effector. These actions recruit the downstream 
ESCRT machinery to synaptic vesicle pools, thereby initiating synaptic vesicle protein 
degradation via the ESCRT pathway. Interestingly, we find that not all synaptic vesicle proteins 
are degraded by this mechanism, suggesting that synaptic vesicles are not degraded as units, but 
rather that SV proteins are degraded individually or in subsets. Moreover, we find that lysine-63 
	  
ubiquitination of VAMP2 is required for its degradation, and we identify an E3 ubiquitin ligase, 
RNF167, that is responsible for this activity. Our findings show that RNF167 and the 
Rab35/ESCRT pathway facilitate the removal of specific proteins from synaptic vesicle pools, 
thereby maintaining presynaptic protein homeostasis. Overall, our studies provide novel 
mechanistic insight into the coupling of neuronal activity with synaptic vesicle protein 
degradation, and implicate ubiquitination as a major regulator in maintaining functional synaptic 
vesicle pools. These findings will facilitate future studies determining the effects of perturbations 
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Chapter 1 - Introduction  
Neuronal Communication 
Neurons have a highly unique morphology that underlies their functionality. They consist of a 
cell soma, dendrites, and axons. The soma is largely responsible for protein synthesis while the 
dendrites and axons extend away from the soma and form connections with other neurons. These 
connections, called synapses, are specialized compartments of neurons that mediate neuronal 
communication. Most classically these are formed between an axonal presynaptic bouton and a 
dendritic postsynaptic spine. On the presynaptic side, neuronal synapses translate electric 
impulses (action potentials) into the regulated release of neurotransmitter from synaptic vesicles 
(SVs) in order to communicate with connecting neurons. These neurotransmitters bind to 
receptors on the postsynaptic neuron, opening ion channels and functioning to create an electrical 
change in postsynaptic membrane potential. If this change in membrane potential reaches a 
threshold, the postsynaptic neuron will fire an action potential and propagate the signal to its 
connecting neurons. 
Synaptic Vesicle Cycle 
The presynaptic bouton is an area of particularly high protein and membrane flux. SVs release 
neurotransmitter by fusing with the neuronal membrane (exocytosis). SV fusion is followed by 
membrane recycling (endocytosis), allowing for SV re-formation and additional rounds of 
neurotransmitter release (Figure 1.1). SV exocytosis and endocytosis depend upon precise 






The exocytosis of SVs is a multi-step process that involves the docking, priming, and fusion of 
SVs with the plasma membrane. In order to be released, SVs filled with neurotransmitter are 
translocated to the presynaptic active zone where they are docked, in a manner that is not well 
understood but is thought to involve Rab3, Munc-18 and a variety of active zone proteins 
(Dulubova et al., 1999; Geppert et al., 1994; Hata et al., 1993). Docking ensures spatial 
regulation of neurotransmitter release by preparing SVs for neurotransmitter release at the active 
zone. Then, the priming machinery, including Munc-13, RIM, and RIM binding proteins, 
functions to promote the partial formation of the soluble NSF attachment protein receptor 
(SNARE) complex (Brose et al., 1995; Wang et al., 1997; Wang et al., 2000). This SNARE 
complex includes the vesicular-SNARE VAMP2 and target-SNAREs syntaxin-1 and SNAP-25 
Figure 1.1 - The synaptic vesicle cycle 
Synaptic vesicles (SVs) filled with neurotransmitter are translocated to the presynaptic active zone where 
they undergo docking and priming. Following an action potential, calcium enters the presynaptic bouton, 
causing vesicles to fuse with the plasma membrane and release neurotransmitter. SV proteins are then 




(Sollner et al., 1993). This priming step prepares the SNARE complex in a manner that ensures 
quick temporal reaction upon an action potential reaching the synapse. The SNARE mediated 
fusion between an SV and the plasma membrane is driven by calcium influx into the presynaptic 
terminal. Calcium binds to the SV integral membrane protein, Synaptotagmin-1, which promotes 
the full zippering of the SNARE complex (Katz and Miledi, 1967; Shao et al., 1998). This 
zippering releases energy which causes SV fusion with the plasma membrane allowing 
neurotransmitter to be released into the synaptic cleft (see (Sudhof, 2004)).  
Endocytosis  
Following exocytosis, it is conventionally believed that SVs fully collapse into the plasma 
membrane. SV proteins and lipids then intermix with plasma membrane components and 
undergo endocytosis to retrieve vesicle constituents. Various forms of endocytosis have been 
observed including clathrin mediated endocytosis (CME), bulk endocytosis, ultra-fast 
endocytosis and “kiss-and-run” endocytosis. CME is the most-studied form of endocytosis and 
occurs in all cell types. Indeed, budding clathrin-coated pits can be observed by electron 
microscopy at the plasma membrane as well as at endosomal cisternae (Heuser and Reese, 1973; 
Miller and Heuser, 1984). However, it has been shown that under high frequency stimulation 
another form of endocytosis, deemed bulk endocytosis, can be observed. This is seen as large 
membrane enfoldings and the formation of endosome-like compartments near the presynaptic 
active zone (Clayton and Cousin, 2008; Miller and Heuser, 1984; Rizzoli and Betz, 2005). It is 
believed that this form of endocytosis allows for quick reversal of membrane expansion under 
high frequency stimulation whereby CME would be rate limiting under these conditions. From 
these bulk endosomal-like structures, SVs can bud off and reform to repopulate the vesicle pool. 
Most recently, another form of endocytosis has been observed in which 100 ms after stimulation, 
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endocytosing vesicles are observed just outside of the active zone (Watanabe et al., 2014). This 
process has been named ultra-fast endocytosis and is believed to represent a mechanism whereby 
plasma membrane expansion by exocytosis is immediately compensated for by endocytosis. 
 Additionally, some evidence supports another model of endocytosis whereby SVs do not 
fully collapse into the plasma membrane but instead form a small transient fusion pore through 
which neurotransmitter is released (Fesce et al., 1994). This differs from ultra-fast endocytosis in 
that it allows for the retention of SV identity and the direct reformation of SVs. Overall, there are 
many models by which SV endocytosis can occur suggesting that different stimuli/activity 
paradigms invoke different mechanisms to compensate for changes in SV exocytosis.  
Endosomal Sorting of Synaptic Vesicles  
For many decades, controversy has surrounded the post-endocytic cycling and reformation of 
SVs. In the early 1970s, two independent studies applied extracellular tracers to neurons of the 
frog neuromuscular junction in order to examine the cycling of SVs. The conflicting findings of 
these studies initiated the controversy surrounding the role of endosomes in SV recycling. 
Heuser and Reese applied high frequency stimulation (10 Hz for 1-15 minutes) to nerve 
terminals and found that the number of SVs per terminal was reduced. This reduction occurred 
together with the formation of large cisternal membranes. Both phenotypes were reversed upon 
rest, suggesting that these cisternae were the precursors to SV replenishment (Heuser and Reese, 
1973). A later study found that clathrin coated vesicles could be observed budding from these 
cisternae, suggesting that endosomes play an intermediary role in reforming SVs after 
endocytosis (Miller and Heuser, 1984). However, another study performed by Ceccarelli et al. 
offered opposing results. While tracer was observed being taken up by synaptic vesicles upon 
stimulation, no reduction in number of SVs and no formation of cisternal structures were 
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observed, suggesting no role for endosomal intermediates in SV recycling (Ceccarelli et al., 
1973). The important difference between these two studies comes down to the stimulation 
paradigm. While Heuser and Reese used high frequency stimulation, Ceccarelli et al. used low 
frequency stimulation (2 Hz for up to 4 hours). The findings from these studies therefore 
suggested that different stimulation paradigms could invoke different forms of endocytosis, 
which varied with regards to their reliance on an endosomal intermediate.  
 Another prominent argument against endosomal sorting in the SV cycle came from a 
study using FM1-43 dye uptake, where it was noted that the amount of FM uptake per vesicle 
was equal to the amount released per vesicle upon exocytosis (Murthy and Stevens, 1998). This 
suggested that no diffusion of dye occurred via the fusion of SVs to an endosomal intermediate. 
However, this study did not address the possibility that other, non-recycling pools of vesicles 
may exchange their membrane with an endosome, nor did it address the idea that SVs may 
undergo homotypic fusion to form synaptic endosomes. This type of fusion is common in non-
neuronal cells, where incoming vesicles fuse to form endosomes (Scita and Di Fiore, 2010) and 
importantly, such fusion would not lead to a dilution of dye. It has been shown in vitro and 
possibly in vivo (Rizzoli et al., 2006; Shimizu et al., 2003) that SVs can undergo homotypic 
fusion, suggesting that SVs can form endosomes. Furthermore, the Ceccarelli study did not 
investigate the cycling of SVs under high activity demands, and therefore did not address the 
idea that synaptic endosomes only form under such stimulation. Indeed, the existence of synaptic 
endosomes has been shown in vivo by immuno-EM at the Calyx of Held synapse and the 
neuromuscular junction (Uytterhoeven et al., 2011; Wucherpfennig et al., 2003). However, these 
endosomes have been shown to be fairly rare and extremely dynamic. Indeed, within mouse 
hippocampal neurons, the large endocytic vesicles formed by ultrafast endocytosis resolve back 
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into SVs within six seconds of stimulation (Watanabe et al., 2014). Though the study by 
Ciccarelli et al. disregarded many potential interpretations, its findings managed to further fuel 
the controversy surrounding the endosomal sorting of SVs.    
 More recent investigations into the composition of SVs have revealed the presence of a 
large number of endosomal proteins on SVs such as diverse endosomal Rab GTPases, endosomal 
SNAREs, endosome-derived coat proteins (Takamori et al., 2006). The presence of these 
proteins on SVs suggests that endosomes do have a role in the SV cycle. Furthermore, 
perturbations in a variety of these proteins lead to changes in neurotransmission and the structure 
and composition of SVs, some of which will be discussed in more detail. Overall these findings 
suggest that endosomal sorting is an important regulatory step in maintaining the fidelity of 
neurotransmission. Although it is now accepted that an endosomal intermediate can play a role in 
the cycling of SVs under certain conditions, the signals and pathways responsible for regulating 
the trafficking and sorting of SV proteins through the endosomal pathway remain poorly 
understood. 
Synaptic Protein Turnover 
While SV endosomal sorting and reformation is becoming better characterized, little remains 
known about the pathways responsible for SV protein degradation. Furthermore, another 
fundamental but unexplored question is how SVs are targeted for degradation. Ubiquitination 
serves as the signal for degradation of soluble proteins by the proteasome, and is also used by 
lysosomal degradation pathways for membrane-bound cargo recognition (Clague and Urbe, 
2010). Intriguingly, a recent study reported that SV membrane proteins are among the most 
highly ubiquitinated neuronal proteins (Na et al., 2012), suggesting that this modification may 
play an important role in their degradation. However, ubiquitination also regulates many non-
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degradative protein trafficking events (i.e. endocytosis, protein-protein interactions), and its role 
in SV protein trafficking/degradation is completely unexplored. 
Ubiquitination 
Ubiquitin is a small protein that is covalently attached to other proteins as a post-translation 
modification to signal for their intracellular transport and degradation. Ubiquitin is conjugated to 
lysine residues on target proteins by a series of enzymes deemed E1, E2, and E3 enzymes. E1s 
are ubiquitin-activating enzymes that transfer ubiquitin to ubiquitin-conjugating enzymes, E2s, 
which then bind the target protein and a ubiquitin-ligase, E3. E3s then covalently attach ubiquitin 
to the target protein by transferring ubiquitin from the E2 to lysine residues on the target 
substrate (Figure 1.2) (Haas et al., 1982; Hershko et al., 1983). Different E3 enzymes are 
responsible for different ubiquitin chain linkages. Both the length of the ubiquitin chain and the 
lysine residue on which the ubiquitin molecule or chain is attached signal for different trafficking 
events ranging from intracellular signaling to degradation (Chau et al., 1989; Hicke and Dunn, 
2003). A variety of proteins responsible for the regulation of protein degradation and trafficking 
contain domains capable of recognizing ubiquitination. These include ubiquitin-interacting 
motifs (UIM), ubiquitin E2-variant (UEV), ubiquitin-associated (UBA), ubiquitin-like (UBL), 
and CUE domains. Finally, ubiquitin must be removed from target proteins in order to maintain a 
pool of free ubiquitin and allow target substrates entrance into degradative structures. This task is 
carried out by deubiquitinating enzymes (DUBs) that cleave ubiquitin at the G76 isopeptide bond 
(see (Helton and Ehlers, 2008)). There are two degradative pathways that recognize ubiquitinated 
proteins: the ubiquitin-proteasome system (UPS) and the Endosomal Sorting Complex Required 




The proteasome is an incredibly abundant structure comprising more than 1% of the total cellular 
protein. Furthermore, they can be found in all neuronal compartments including the presynaptic 
terminal. The eukaryotic proteasome is comprised of two multimeric complexes, the catalytic 
20S core particle and two 19S regulatory complexes. Four heptameric rings that contain various 
proteolytic sites form a cylinder that is the 20S core particle. Each 19S regulatory complex is 
made up of eight subunits and a ring of 6 AAA family ATPases that gate the lumen of the 20S 
core and regulate the energy-dependent unfolding of proteins necessary for entrance into the core 
(see (Tanaka, 2009)). Multiple components of the 19S regulatory complex are capable of 
ubiquitin recognition on target proteins (Lam et al., 2002). Specifically, lysine 48-linked poly-
ubiquitination is known to serve as a signal for protein degradation by the proteasome. Typically, 
Figure 1.2 – Ubiquitination 
Ubiquitination is a post-translation modification that occurs via the covalent attachment of ubiquitin to target 
proteins. Ubiquitin is activated by an E1 enzyme and then conjugated to an E2 enzyme. An E3 ligase then 
simultaneously binds the E2 enzyme and the target protein, and functions to transfer ubiquitin from the E2 to the 
target protein.  
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at least four lysine-48 linked ubiquitin molecules are necessary to bind the proteasome (Kish-
Trier and Hill, 2013).  
Roles of UPS at the Synapse 
The UPS plays an intimate role in both synapse formation and in the regulation of synaptic 
function. Dysregulation in the ubiquitination and degradation of a variety of proteins can lead to 
defects in synapse formation and elimination as well as axonal growth, steering and pruning. In 
mature neurons, the UPS continues to play an important role in regulating neurotransmitter 
release, the composition of the postsynaptic density (PSD), and synaptic plasticity. Intriguingly, 
many of these processes are tightly linked to neuronal activity (Alvarez-Castelao and Schuman, 
2015) suggesting a coupling between neuronal activity and UPS function.  
 Indeed, ubiquitination and degradation of certain postsynaptic proteins can occur in an 
activity-dependent manner (Ehlers, 2003; Lussier et al., 2011; Schwarz et al., 2010; Scudder et 
al., 2014). Specifically, the abundance of various PSD proteins changes in response to changes in 
neuronal activity levels in a proteasome-dependent manner (Ehlers, 2003). Furthermore, the 
global ubiquitination state of the PSD increases with increasing neuronal activity and decreases 
with neuronal silencing, suggesting that ubiquitination of these proteins is tightly linked to 
neuronal activity (Ehlers, 2003). While few studies have examined the relationship between 
activity and presynaptic protein turnover, it has been reported that silencing neurons leads to the 
down regulation of presynaptic scaffolding protein levels (e.g. Piccolo/Bassoon, Munc13, RIM) 
that is partially restored by blocking the proteasome. Interestingly, this silencing also leads to an 
accumulation of SV proteins (i.e. SV2B, synaptotagmin-1, vGlut1), suggesting that presynaptic 
proteins levels are differentially regulated by changes in neuronal activity (Lazarevic et al., 
2011). 
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Ubiquitin-Mediated Endosomal Sorting 
Ubiquitination also serves as a signal for sorting through the endocytic pathway. Endocytosed 
proteins can be sent to endosomes where they are then sorted for recycling back to the plasma 
membrane, retrograde transport to the secretory pathway, or degradation by the lysosome. Multi-
monoubiquitination and Lysine-63 (K63)-linked polyubiquitination target proteins for 
degradation through interactions with the ESCRT pathway.  The ESCRT pathway is comprised 
of a series of protein complexes (ESCRT-0, –I, –II, -III) that are sequentially recruited to the 
endosomal membrane. It is believed that the ESCRT-0 protein, Hrs, is first recruited to the 
endosomal membrane through its FYVE domain, a lipid-binding domain that preferentially 
interacts with phosphoinositol 3-phosphate (PI3P) the phosphoinositide enriched on early 
endosomes. Proteins of the ESCRT-0, -I and -II complexes contain various ubiquitin recognition 
motifs and function to sort and retain ubiquitinated proteins in microdomains on the endosomal 
membrane (Figure 1.3). The ESCRT-III complex functions to form intraluminal vesicles (ILVs) 
by inducing membrane deformation and recruiting accessory proteins for the budding and 
abscission of ILVs from the endosomal membrane. Once an endosome contains two or more 
ILVs, it is deemed a multivesicular body (MVB). The cargo contained within the ILVs is 
destined for lysosomal degradation (see (Raiborg and Stenmark, 2009)).  
Figure 1.3 - Recognition of ubiquitination by the ESCRT pathway 




Axonal transport of MVBs  
Lysosomes are rarely detected in axons and presynaptic boutons. Although LysoTracker and 
LAMP1 positive structures can be localized to axons, it is becoming increasing evident that these 
structures are not fully mature functional lysosomes. Indeed, a recent study has determined that 
there are distinct populations of lysosomes in neurons and that those located in axons are 
strikingly deficient in lysosomal proteases (Gowrishankar et al., 2015). This finding corroborates 
those of others who have shown that endocytic and autophagosomal vesicles mature via 
increasing acidification concomitantly with their retrograde transport (Hollenbeck, 1993; Maday 
et al., 2012; Overly and Hollenbeck, 1996).  
 Although MVBs are major intermediates in the endo-lysosomal pathway, little is known 
regarding the dynamics of MVB formation and transport within axons. A plethora of work has 
shown that various cargos, including cannabinoids, tracers, and SV markers, can be found within 
MVBs in axons (Lees et al., 1981; Vitalis et al., 2008), suggesting that MVBs are responsible for 
the retrograde transport of these cargo. Interestingly, other cargo that is seen to accumulate in 
somatic MVBs, such as trophic factors, are not detected in axonal MVBs, suggesting that other 
endocytic vesicles are responsible for this transport (Altick et al., 2009). Together, these studies 
suggest that the endocytic vesicles for retrograde transport are cargo-specific. 
Interestingly, MVBs can be detected in presynaptic boutons by electron microscopy (EM) 
(Ceccarelli et al., 1973; LaVail and LaVail, 1975; Teichberg et al., 1975) and often appear 
following neuronal stimulation (Teichberg et al., 1975), suggesting that their formation may be 
activity-dependent. However, so far the studies addressing synaptic and axonal MVBs employ 
static imaging techniques, namely EM, and fail to give a dynamic picture of MVB formation and 
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transport. Additionally, the proteins responsible for regulating cargo sorting and vesicular 
trafficking through the endolysosomal pathway are largely uncharacterized in neurons.   
Rab GTPases 
The Rab family of small GTPases are important regulators of membrane trafficking in all 
eukaryotic cells. Rab GTPases act as “molecular switches” that cycle between ‘active’ (GTP-
bound) and ‘inactive’ (GDP-bound) states. Although Rab GTPases have intrinsic GTPase 
activity, the hydrolysis of GTP to GDP is further aided by GTPase activating proteins (GAPs), 
which facilitate the inactivation of Rabs. On the other hand, the activation of Rabs is catalyzed 
by guanine nucleotide exchange factors (GEFs), which release GDP and allow Rabs to bind 
cytosolic GTP. GTP-bound Rabs in turn recruit effectors that specifically recognize activated 
Rabs, and catalyze downstream events such as membrane fusion (i.e. SNARE proteins) and 
vesicle trafficking (i.e. motor proteins, Figure 1.4) (see (Stenmark, 2009)). Thus, regulation of 
Rab activation/inactivation by GEFs and GAPs allows for spatiotemporal coordination of critical 
membrane trafficking events.  
Figure 1.4 - Rab GTPase cycle 
Rab GEFs function to activate Rab proteins by catalyzing the exchange of GDP for GTP. Active Rabs then 
recruit effectors to mediate downstream trafficking events. Rab GAPs function to inactivate Rab proteins by 
hydrolyzing GTP to GDP. 
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As key regulators of vesicle trafficking, Rab GTPases are hypothesized to regulate 
multiple steps of the SV life cycle, from biogenesis to recycling and degradation. Among the >60 
Rabs in mammalian brain, at least 30 are reported to associate with SV pools (Pavlos and Jahn, 
2011; Takamori et al., 2006). However, only a few of these (e.g. Rab3, Rab27) have well-
established roles in the SV cycle (Mahoney et al., 2006; Pavlos et al., 2010; Schluter et al., 2004; 
Schluter et al., 1999; Yu et al., 2008). While Rab3 has a well-characterized role in exocytosis 
(see (Regazzi, 2007)) in non-neuronal cells and is found on synaptic vesicles, its genetic loss-of-
function was found to have minimal effects on synaptic transmission (Geppert et al., 1994). 
However, it was later found that Rab3 GEFs also act on Rab27, suggesting Rab27 can 
compensate for Rab3 in SV exocytosis. Indeed, the loss of both Rab3 and Rab27 leads to a 
dramatic decrease in SV exocytosis (Mahoney et al., 2006). These findings suggest that the Rab 
GTPases have critical regulatory roles in the SV cycle. 
Endocytic SV-associated Rab GTPases 
Lending credence to the proposed role of endosomal sorting in the SV cycle, many of the SV-
associated Rabs identified have known endocytic functions in non-neuronal cells (Hoopmann et 
al., 2010; Rizzoli et al., 2006; Takamori et al., 2006; Uytterhoeven et al., 2011; Wucherpfennig 
et al., 2003), though many questions remain regarding their roles in neurons. For example, it is 
not known how and where specific Rab GTPases act at the synapse to mediate SV protein sorting, 
although recent evidence implicates presynaptic endosomes as important sites of Rab-mediated 
SV protein sorting (Hoopmann et al., 2010; Rizzoli et al., 2006; Shimizu et al., 2003; Takamori 
et al., 2006; Uytterhoeven et al., 2011; Wucherpfennig et al., 2003). As mentioned previously, 
the early endosome-associated Rab5 is present on recycling SVs (Hoopmann et al., 2010; Pavlos 
et al., 2010; Shimizu et al., 2003; Takamori et al., 2006; Wucherpfennig et al., 2003) and Rab5 
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loss-of-function has been shown to impair SV recycling and neurotransmitter release in 
Drosophila (Shimizu et al., 2003; Wucherpfennig et al., 2003).  
Another study in Drosophila has demonstrated that endosomal sorting and replenishment 
of SV proteins is necessary to maintain a releasable pool of SVs, and that this process requires 
Rab35 (Uytterhoeven et al., 2011). The ESCRT system and the pre-lysosomal homotypic fusion 
and vacuole protein sorting (HOPS) complex were also identified through genetic interactions as 
components of this pathway (Fernandes et al., 2014; Uytterhoeven et al., 2011). Specifically, 
these studies have demonstrated that loss-of-function of Skywalker/TBC1D24, a Rab GAP, leads 
to Rab35 over-activation and the excessive endosomal sorting and replenishment of SV proteins 
in Drosophila. Additionally, alterations in Rab7 and Rab11 activation have been reported to 
affect neurotransmission at the neuromuscular junction (Uytterhoeven et al., 2011), suggesting 
that the trafficking routes of SVs are complex and highly dependent upon the Rab GTPases.  
Interestingly, some of these SV-associated Rabs (i.e. 5, 11, 26) are implicated in 
macroautophagy (Ao et al., 2014; Binotti et al., 2015), another lysosomal degradative pathway 
that may also be important for SV protein turnover. Macroautophagy begins with the de novo 
synthesis of a pre-autophagosomal structure (PAS). This membrane expands to engulf 
cytoplasmic contents, which can include protein aggregates and whole organelles. Eventually, 
the membrane closes and forms a double membrane structure referred to as an autophagosome 
(see (Feng et al., 2014)). Autophagosomes can then fuse with compartments of the endocytic 
pathway (i.e. early endosomes, MVBs) to form an intermediate structure called an amphisome, 
which will then fuse with lysosomes, or autophagosomes can directly fuse with lysosomes (see 
(Fader and Colombo, 2009)). While autophagy functions at a basal level to degrade cellular 
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contents, it can also be highly upregulated in response to stress such as nutrient deprivation (see 
(Russell et al., 2014)). 
 Indeed, macroautophagy has been shown to mediate the degradation of SVs under 
certain conditions (Hernandez et al., 2012). In neurons, stimulating autophagy with rapamycin 
was shown to reduce SV pool size and evoked neurotransmission in dopaminergic neurons 
(Hernandez et al., 2012). Moreover, another SV-associated Rab (Rab26) appears to link SV 
clusters to the macroautophagy machinery by recruiting Atg16L1, a component of pre-
autophagosomes (Binotti et al., 2015). In addition, a forward genetic screen in Drosophila 
recently identified presynaptic voltage-gated calcium channels as key regulators of 
autophagosome-lysosome fusion, indicating that components of the presynaptic SV release 
machinery also function in autophagic degradation (Tian et al., 2015). These studies provide 
evidence that macroautophagy can regulate SV pool size, but it is unclear whether this pathway 
is essential for the basal turnover/degradation of SV proteins. Thus, the pathway(s) for SV 
protein degradation, and the roles of SV-associated Rabs in regulating this process, remain 
unresolved. 
Protein Homeostasis in Neuronal Health 
A clear connection between a variety of neurodegenerative diseases and synaptic protein 
homeostasis has led to a great interest in understanding the basic mechanisms involved in this 
process. While all cells must degrade damaged or dysfunctional proteins, the structure and 
function of neurons and their synapses necessitates specialized mechanisms to maintain healthy 
proteins throughout the lifetime of an organism. Whereas other cell types can undergo complete 
turnover, the embedded nature of neurons within a network and the specialization of synapses to 
encode specific information precludes this possibility. Although there is the potential for entire 
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synapses to turnover, this has only been observed in the barrel cortex and at neuromuscular 
junctions (Grillo et al., 2013; Shi et al., 2012; Zuo et al., 2005). 
The presynaptic compartment in particular is an area of high membrane dynamics. In 
order for neurons to maintain efficient neurotransmission, SVs must undergo repeated cycles of 
exocytosis, endocytosis, and vesicle reformation. These processes depend upon SV-associated 
proteins whose proper conformation and function are of paramount importance to neuronal 
health (Bezprozvanny and Hiesinger, 2013; Wang et al., 2013). Indeed, the buildup of damaged 
or misfolded SV proteins can lead to synaptic dysfunction and neurodegeneration (Garden and 
La Spada, 2008; Scott et al., 2010; Uytterhoeven et al., 2011). However, despite the importance 
of SV protein turnover for neuronal health, the molecular mechanisms underlying this process 














Chapter 2 - Materials and Methods  
Cell Culture 
Cultured rat neurons 
Timed-pregnant Sprague Dawley rats were housed, handled, and euthanized using methods 
consistent with recommendations from the Guide for the Care and Use of Laboratory Animals 
prepared by the National Research Council, and with the Columbia University Medical Center 
Institutional Animal Care and Use Committee. Hippocampal neurons were prepared from rat 
brains (E18) using a modified Banker culture protocol (Banker and Goslin, 1998; Waites et al., 
2009). Briefly, neurons were dissociated in TrypLE Express (Fisher/Life Technologies) for 20 
minutes, washed with Hank’s Balanced Salt Solution (Sigma) and plated in Neurobasal medium 
with B27 supplement and Glutamax (all Life Technologies) at a density of 250,000 neurons per 
well (12 well plates) or coverslip (22x22 mm square).  
Microfluidic culturing 
Primary hippocampal neurons were plated in two adjacent channels of a three-channel 
microfluidic chamber at a density of 60,000 neurons in the larger channel and 40,000 neurons in 
the smaller channel. Half the media of all channels was changed every 48 hours. On 7 days in 
vitro (DIV), fluidic isolation was performed to preferentially transduce neurons in the larger 
channel with mCh-Hrs virus. A volume difference of 60 µl was maintained between the 
transduced and untransduced channels (Park et al., 2006). Prior to imaging, fluorescence was 




Sources of the constructs used are listed in Table 2.1. For shRNAs, target sequences for rat 
Rab35, Hrs, and TSG101 were modified from published work or designed using siDirect 
(sidirect2.rnai.jp). Target sequences are as follows:  Rab35: 5’- 
GGGCAGATGGGGATCCAGC-3’ (nucleotides 418-436)(Allaire et al., 2010) Hrs: 5’-
GAACTACTGGGAGAAGAAA-3’ (nucleotides 996-1014), TSG101: 5’- 
GGATGAAGGAGGAAATGGA-3’ (nucleotides 725-743), RNF167: 5’-
CCAAAGAGCAACTGAAACA-3’ (nucleotides 626-644). shRNAs were sub-cloned into pZOff 
2.0 and subsequently into the modified FUGW H1 vector as described previously (Leal-Ortiz et 
al., 2008). To evaluate shRNA knockdown efficiency, neurons were transduced with lentivirus 
on 3-7 DIV, collected on 12-16 DIV, and processed for immunoblotting as described below. 
Protein intensity was measured and compared to that in neurons expressing a scrambled hairpin 
(scRNA). Transduction was timed to achieve the highest knockdown efficacy without noticeable 
toxicity (assessed by bright field microscopy). To create shRab35-resistant Rab35, the following 
mutations (shown in italics) were made to rat Rab35 5’-GGCCAAATGGGCATTCAAC-3’ 
(nucleotides 418-436). Neurons were transduced with either scRNA or shRab35 on 3 DIV then 
on 9 DIV with sh-resistant Rab35. 
qPCR 
RNA was isolated from 14 DIV primary hippocampal neurons using Qiagen RNeasy Micro kit. 
Reverse transcription was then performed using SuperScript VILO master mix (Invitrogen) 
followed by qPCR using TaqMan primers to RNF167, GAPDH, and actin. Each reaction was 
performed in triplicate and quantified using the ΔΔCt method (Livak and Schmittgen, 2001). 
RNF167 RNA levels were normalized to actin RNA and to GAPDH RNA levels. The average 
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normalized RNF167 RNA value was calculated and compared between soluble-GFP expressing 
control neurons and shRNF167 expressing neuron.   
Lentivirus production, transduction, and DNA transfection 
Lentivirus was produced as previously described (Leal-Ortiz et al., 2008; Lois et al., 2002) 
except that Calfectin (SignaGen Laboratories) was used for transfection of HEK293T cells. HEK 
medium was replaced with Neurobasal medium 18-24 hours after transfection, and this medium 
(viral supernatant) was harvested 24 hours later. Neurons were transduced with 50-200 µl 
lentiviral supernatant/well (6 or 12 well plates) between 3-10 DIV depending on the experiment 
(see Results), and processed for immunoblotting or immunocytochemistry between 14-15 DIV. 
For biochemical experiments, high viral titer producing >80% infectivity was ensured by 
transducing test wells of neurons with varying amounts of virus, and calculating of the number of 
infected cells divided by the number of DAPI-positive nuclei (DAPI VectaShield, Vector 
Laboratories) per field of view using fluorescence microscopy.  
 Neurons were transfected using Lipofectamine 2000 (Life Technologies) on 7-10 DIV. 
For each 22x22 mm coverslip, 2.5 µl Lipofectamine was incubated with 62.5 µl Neurobasal for 5 
minutes, combined with 1-2.5 µg DNA diluted in 62.5 µl Neurobasal for 20 minutes, then added 
to neurons for 45 minutes at 37ºC. Neurons were transfected in Neurobasal medium containing 
50 µM AP5 and 10 µM CNQX, and returned to their original dishes and medium following 
transfection. Neurons were fixed for immunofluorescence microscopy on 12-16 DIV.   
Pharmacological treatments  
Pharmacological agents were used in the following concentrations and time courses: 
cycloheximide (Calbiochem, 0.2 µg/µl, 24hrs), bicuculline (Sigma, 40 µM, 12-24hrs), 4-
aminopyridine (Tocris, 50 µM, 12-24hrs), AP5 (Tocris, 50 µM, 24 hrs), CNQX (Tocris, 10 µM, 
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24hrs), tetrodotoxin (Tocris, 0.5 µM, 24hrs), GDP (Sigma, 5 mM), GTPγs (Sigma, 5 mM), PR-
619 (LifeSensors, 50 µM, 6hrs).  
Electrophysiology 
Changes in neuronal activity in the presence of bicuculline/4-aminopyridine or 
CNQX/APV/TTX were measured using whole-cell voltage clamp electrophysiology. Dissociated 
hippocampal neurons were recorded on 15 DIV at room temperature using a Multiclamp 700B 
amplifier (Molecular Devices) and a 1550A Digidata digitizer (Molecular Devices) interfaced to 
a computer equipped with Clampex 10 software (Molecular Devices). Neurons were 
continuously perfused with extracellular solution (140 mM NaCl, 2.4 mM KCl, 10 mM HEPES, 
10 mM glucose, 4 mM CaCl2, 4 mM MgCl2; pH 7.35, 300 mOsm) via a gravity-based perfusion 
system. Patch pipettes pulled from borosilicate glass (World Precision Instruments) had 
resistances of 4-5 MΩ when filled with intracellular solution (135 mM K-gluconate, 10 mM 
HEPES, 1 mM EGTA, 4.6 mM MgCl2, 4 mM Na-ATP, 15 mM creatine phosphate; pH 7.35, 320 
mOsm). The series resistance was <15 MΩ and experienced minimal change (<15 %) from the 
start of the recording to the end of the recording. The membrane potential was clamped at -70 
mV. Following baseline activity recordings for 4 minutes, either 40 µM bicuculline/50 µM 4-
aminopyridine or 10 µM CNQX/50 µM APV/0.5 µM TTX was perfused onto the neurons and 
recording continued for a further 6 minutes. Traces were analyzed using MiniAnalysis software. 
Activity was measured as the frequency of spontaneous events during the first 4 minutes 
(baseline) and the last 4 minutes (with drug) of the trace. 
Imaging techniques  
Immunofluorescence microscopy 
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Primary antibodies are listed in Table 2.2. Alexa 488- or Alexa 647-conjugated secondary 
antibodies (Life Technologies) were used at 1:800 or 1:400, respectively. Neurons were 
immunostained as described previously (Leal-Ortiz et al., 2008). Briefly, coverslips were fixed 
with Lorene’s fix (60 mM PIPES, 25 mM HEPES, 10 mM EGTA, 2 mM MgCl2, 0.12 M 
Sucrose, 4% formaldehyde) for 15 minutes, primary and secondary antibody incubations were 
performed in blocking buffer (2% glycine, 2% BSA, 0.2% gelatin, 50 mM NH4Cl in 1X PBS) for 
1-2 hours at room temperature or overnight at 4oC, and all washes were done with PBS. 
Coverslips were mounted with DAPI VectaShield (Vector Laboratories) and sealed with clear 
nail polish. Images were acquired with a 40X objective (Neofluar, NA 1.3) or a 63X objective 
(Neofluar, NA 1.4) on an epifluorescence microscope (Axio Observer Z1, Zeiss) with Colibri 
LED light source, EMCCD camera (Hamamatsu) and Zen 2012 (blue edition) software.   
Confocal microscopy 
Super-resolution imaging was performed with a Zeiss LSM 800 confocal microscope equipped 
with Airyscan module, using a 63x objective (Plan-Apochromat, NA 1.4). Images were obtained 
and processed using Zen Blue 2.1 software.  
SNAP-labeling 
SNAP-Cell Oregon Green (New England BioLabs) was diluted in Neurobasal media to a final 
concentration of 10 µM. 13 DIV neurons were incubated for 30 minutes at 37ºC, washed 3 times 
with Neurobasal media, incubated for 30 minutes at 37ºC in fresh media, washed once more, and 
returned to the original media (adapted from (Bodor et al., 2012)). 15 hrs and 2 days after SNAP 
labeling, neurons were fixed, immunostained using anti-Flag antibody, and imaged as described 
above.  
Super-Ecliptic pHluorin imaging 
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Neurons were lentivirally transduced with super-ecliptic pHluorin (SEP)-tagged WT or K/R 
mutant VAMP2 or synaptophysin on 2-3 DIV, and imaging experiments performed between 13-
16 DIV. SEP fluorescence is quenched inside acidic SVs, increased upon exposure to the neutral 
extracellular pH during stimulation, and re-quenched after endocytosis, thus enabling us to 
visualize the kinetics of SV exo/endocytosis via changes in SEP fluorescence, as in (Burrone et 
al., 2006; Voglmaier et al., 2006). Images were acquired every 5 seconds for 5 cycles prior to 
stimulation, 6 cycles during 10Hz, 30 sec stimulation, and 49 cycles following stimulation. At 
the end of each experiment, NH4Cl Tyrodes was added to de-acidify neurons, allowing us to 
visualize total SEP fluorescence and to measure the size of the recycling pool of SVs (maximum 
SEP fluorescence during stimulation) as a fraction of total SV pool (SEP fluorescence after 
NH4Cl Tyrodes treatment). To plot SV exo/endocytosis curves, fluorescence changes of 
individual SEP puncta over time were measured with an ImageJ plugin (Time Series Analyzer v2, 
author Balaji), and normalized to initial fluorescence intensity. For each coverslip, an average 
curve was calculated from individual punctum intensity values. These curves were combined to 
plot average curves for each condition. 
Live Imaging  
Neurons were plated in microfluidic chambers on glass bottom dishes. On 7 DIV, neurons were 
lentivirally transduced with mCh-Hrs virus. On 10 DIV, time series images taken every 5 
seconds for 50 frames were acquired with a 40X objective (Zeiss Neofluar, NA 1.3) on an 
epifluorescence microscope (Axio Observer Z1, Zeiss) with Colibri LED light source, EMCCD 
camera (Hamamatsu) and Zen 2012 (blue edition) software. Neurons were treated with 
bicuculline and 4-AP to increase neuronal activity for 1 hour. Puncta direction and velocity were 
analyzed using the Manual Tracking plugin (Frabrice Cordeli) in ImageJ. Average velocity was 
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calculated for all puncta in a given axon. Puncta were classified as primarily moving if any 
movement was observed in >45% of frames. The directionality of moving puncta was further 
classified as primarily anterograde or primarily retrograde if a puncta moved in a given direction 
for >45% of frames or bidirectional if neither direction was favored in >45% of frames.  
Electron Microscopy 
On 14 DIV, neurons plated on Lab-Tek chamber slides (Nunc) were treated with bicuculline and 
4-AP for 12 hours. Following this treatment, cells were then fixed with glutaraldehyde and then 
dehydrated, embedded, sectioned, stained and subjected to electron microscopy at Columbia 
University’s Pathology Imaging Core. 
Biochemical techniques 
Co-immunoprecipitation and pull-down assays 
For co-immunoprecipitation studies, HEK293T cells were transfected using Calfectin according 
to manufacturer’s protocol (SignaGen Laboratories). Cell lysates were collected 48 hours after 
transfection in lysis buffer (50 mM Tris-Base, 150 mM NaCl, 1% Triton X-100, 0.5% 
deoxycholic acid) with protease inhibitor cocktail (Roche) and clarified by centrifugation at high 
speed (20000 rcf). For neuronal co-immunoprecipitation and pull-down studies, neurons were 
transduced between 7-10 DIV and collected in lysis buffer on 14-15 DIV. Neuronal lysates were 
centrifuged at low speed (1000 rcf) to pellet nuclei. Resulting supernatant from HEK293T cells 
or neurons was incubated with Dynabeads (Life Technologies) coupled to anti-Flag 
(monoclonal; Sigma), anti-mCherry (polyclonal; Biovision), anti-HA (monoclonal; Santa Cruz), 
anti-VAMP2 (monoclonal; Synaptic Systems), or anti-GTP-Rab35 (NewEast Biosciences) 
antibodies. For all studies, lysates were incubated at 4ºC under constant rotation for 1-2 hours. 
Beads were washed 2-3 times with PBS containing 0.05% Triton (PBST) then once with PBS. 
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Bound proteins were eluted using sample buffer (Bio-Rad) and subject to SDS-PAGE 
immunoblotting as described below. For active GTP-Rab35 immunoprecipitation experiments, 
2.5 mM MgCl2 was added to all buffers. 
For co-immunoprecipitation studies assessing the nucleotide dependence of the Rab35-
Hrs interaction, lysates from HEK293T cells co-transfected with Flag-Hrs and HA-Rab35 were 
collected and clarified as above. The resulting supernatant was divided equally and treated with 
either 5 mM GDP or 5 mM GTPγs. Lysates were incubated at 37ºC with agitation for 30 minutes 
to facilitate nucleotide exchange. Lysates were briefly chilled on ice, treated with 60 mM MgCl2 
to lock Rab35 in either the GDP or GTP bound state, and then subjected to immunoprecipitation 
with anti-Flag coated Dynabeads. Bound proteins were washed as described with wash buffer 
containing 2.5 mM MgCl2, then eluted in sample buffer.  
Ubiquitination assay for VAMP2  
HA-ubiquitin was co-transfected with either untagged WT VAMP2 or untagged KR VAMP2 in 
HEK293T cells. For RNF167 ubiquitination assays, HA-ubiquitin was co-transfected with 
untagged WT VAMP2 and either soluble mCh or mCh-RNF167. Prior to collection, cells were 
incubated with 50 µM PR-619 (LifeSensors), a deubiquitination inhibitor, for 6 hours. Cell 
lysates were collected and clarified as described in above. Resulting supernatant from HEK293T 
cells was incubated with Dynabeads (Life Technologies) coupled to anti-VAMP2 (monoclonal; 
Synaptic Systems) antibodies. Lysates were incubated for 12 hours at 4ºC under constant rotation. 
Beads were washed 3 times with PBS. Bound proteins were eluted using sample buffer (Bio-
Rad) and subject to SDS-PAGE immunoblotting as described.  
GST Pull-down  
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GST and GST-Rab35 protein purification and pull-down were performed as described previously 
(Brymora et al., 2004) with minor changes. Specifically, protein expression was induced with 0.4 
mM IPTG overnight at 25ºC, bacterial cell pellets were resuspended in a solution containing 50 
mM Tris, 150 mM NaCl, 2.5 mM MgCl2 with protease inhibitors at pH 7.4, and cells were 
subsequently lysed in the same buffer with 0.5% Triton X added. GST, GST-Rab35-GDP or 
GST-Rab35-GTPγs were coupled to agarose beads, then incubated with HEK293T lysate 
expressing Flag-Hrs for 2 hours at 4ºC under constant rotation. Beads were then washed 3 times 
in 50 mM Tris, 150 mM NaCl, 2.5 mM MgCl2, 0.5% Triton X with protease inhibitors and once 
in the same buffer without Triton. Proteins were eluted directly in 2X SDS sample buffer (Bio-
Rad) and processed for immunoblotting as described below. For all co-immunoprecipitation and 
pull-down assays, 1-5% of lysate applied to the beads was run as ‘input’. 
Immunoblotting 
For all other immunoblotting experiments, neurons were collected directly in 2X SDS sample 
buffer (Bio-Rad). Samples were subjected to SDS-PAGE, transferred to nitrocellulose 
membranes, probed with primary antibody (Table 2.2) in 5% BSA/PBS+0.05% Tween-20 
overnight at 4oC, followed by DyLight 680 or 800 anti-rabbit, anti-mouse, or anti-goat secondary 
antibodies (Thermo Scientific) for 1 hour. Membranes were imaged using an Odyssey Infrared 
Imager (Model 9120, LI-COR Biosciences). Protein intensity was measured using the ‘Gels’ 
function in ImageJ.  
Analysis 
Fold-change calculation 
For cycloheximide-chase experiments, the normalized intensity of protein remaining after 24 
hours of treatment was reported as a fraction of the normalized intensity of that protein in lysates 
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from the same condition with DMSO treatment. Protein levels were first normalized to the 
intensity of tubulin. Next, the fractional amount of degradation that occurred for each protein 
over the 24-hour period was calculated by dividing its intensity with cycloheximide treatment 
(chx) to its intensity with DMSO control treatment (c)(Table 3.1). These fractional amounts of 
degradation were further normalized to “fold change in degradation vs. control” by dividing the 
perturbation condition (i.e. blockers, Bic/4AP, shRNA) by the control condition (i.e. DMSO, 
scRNA).  
Image Analyses 
Colocalization analyses of Hrs and CHMP2B with VAMP2 were performed manually in ImageJ 
using the Time Series Analyzer V2 plugin (Balaji) to create ROIs (8x8, oval) over Hrs or 
CHMP2B puncta. ROIs with VAMP2 immunostaining above a threshold value (determined 
empirically, typically <5% in Threshold window) were counted and expressed as a fraction of 
the total. Puncta intensity analyses were performed in ImageJ by creating a selection in the Rab 
channel and applying it to the VAMP2 channel. Mean intensity values of VAMP2 puncta (‘gray 
values’) were then measured using the ‘Analyze Particles’ function. The experimental condition 
was reported as a fraction of the control condition by dividing intensity values from three 
experimental images by the average of three images from the control condition. In experiments 
coexpressing shHrs or scrambled shRNAs with mCh-Rab35, VAMP2 intensity was measured in 
OpenView (written by Noam Ziv, Technion Institute, Haifa, Israel) as described previously 
(Waites et al., 2011). Briefly, VAMP2 puncta were selected from processes expressing both 
EGFP and mCh-Rab protein, mean intensity values were measured, and average intensity 
calculated and reported as in the ImageJ analyses. Puncta per unit length (measured in arbitrary 
units) was calculated in ImageJ using the ‘freehand line’ tool to trace and measure Tau positive 
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axons containing Hrs puncta. To measure BG-Oregon Green colocalization with Flag, the 
ImageJ colocalization plug-in (Pierre Bourdoncle) was used. BG-Oregon Green and Flag puncta 
above a threshold value were determined empirically, total vs. colocalized puncta counts were 
measured using the ‘Analyze Particles’ function, and the fraction of colocalized puncta over total 
Flag puncta calculated. OpenView was used to measure BG-Oregon Green intensity as described 
above.    
Evaluation of neuronal health 
14 DIV hippocampal neurons on coverslips were treated with 0.2 µg/µl cycloheximide for 24-36 
hours, fixed in Lorene’s Fix, and processed for immunostaining against Tau (polyclonal; 
Synaptic Systems) and MAP2 (monoclonal; Sigma), mounted with DAPI Vectashield (Vector 
Laboratories), and images acquired as described (Immunofluorescence Microscopy section). The 
following features were scored per field of view: condensed nuclei (DAPI staining in MAP2 
positive neurons), enlarged cell bodies (DAPI/MAP2 area), blebbing dendrites (based on MAP2 
staining), and axonal beading (punctate Tau staining). In control conditions, <15% of neurons 
exhibited one or more of these features.  
Statistical analyses 
Graphing and statistics were performed using Prism (GraphPad). Unpaired, two-tailed t-tests 















species accession # source Vector and cloning information 







Subcloned into pEGFP/mCh-C2 
and pKH3 vectors at EcoRI site, 
moved into FUGWm with 
MfeI/NheI and EcoRI/XbaI 
(FUGWm), PCR into pGEX-4T2 at 
SalI/NotI sites  




Received in pEGFP vector 
subcloned mCh at AgeI/BsrGI sites, 
moved into FUGWm using 
MfeI/NheI and EcoRI/XbaI 
(FUGWm) 
Rab5 human  Gift from 
G. DiPaolo 
 
Received in pEGFP, subcloned 
mCh at AgeI/BsrGI sites, moved 
into FUGW using MfeI/NheI, PCR 
into pKH3 at BamHI/ClaI sites 






Subcloned into pEGFP/mCh-C2 
and pKH3 vector at EcoRI site, 
moved into FUGWm with 
MfeI/NheI and EcoRI/XbaI 
(FUGWm) 







Subcloned into pEGFP/mCh-C2 
and pKH3 vector at EcoRI site, 
moved into FUGWm with 
MfeI/NheI and EcoRI/XbaI 
(FUGWm) 




Subcloned into pKH3 vector at 
EcoRI site 
Hrs human  Addgene 
#29685 
 
Received in RFP vector, moved into 
FUGWm using MfeI/NheI, PCR 
into pCS2-FLAG at XhoI/XbaI sites 
TSG101 human  Addgene 
#38318 
 
Received in mCh vector, used as is 
STAM human  Addgene 
#21499 
 
Subcloned into pmCh N1 at 
XhoI/HindIII sites 
CHMP2B human  Gift from 
C. Garner 

















Subcloned into pEGFP/SEP-N1 
vectors at EcoRI site, moved into 
FUGWm with MfeI/NheI and 
EcoRI/XbaI (FUGWm) 





Subcloned into pEGFP/SEP-N1 
vectors at EcoRI site, moved into 
FUGWm with MfeI/NheI and 
EcoRI/XbaI (FUGWm) 
HA-Ubiquitin human  Addgene 
#18712 









































Antibody Source Species Catalog number 
VAMP2 Synaptic Systems rabbit 104202 





Tubulin Abcam rabbit ab4074 
Tubulin Sigma mouse t9026 
mCherry Biovision rabbit 5993 
Hrs Santa Cruz rabbit m-79 sc30221 
Rab35 Gift from Peter 
McPherson 
rabbit  
Synaptotagmin 1 Synaptic Systems rabbit 105012 
Snap-25 Synaptic Systems mouse 111011 
Rim1α Synaptic Systems rabbit 140003 
Munc-13 Synaptic Systems rabbit 126102 
Synaptophysin Santa Cruz rabbit h-93 sc9116 
HA Santa Cruz rabbit y-11 sc805 
HA Santa Cruz mouse f-7 sc7392 
Flag Sigma mouse clone m2 f3165 
TSG101 Santa Cruz mouse c-2 sc7964 
Tau Santa Cruz rabbit v-20 sc1996 
MAP2 Sigma mouse ap-20 m1406 
Synapsin 1 Synaptic Systems mouse 106001 
Rab3 Synaptic Systems mouse 107111 
Rab5 Santa Cruz mouse D-11 sc-46692 
Rab10 Santa Cruz goat C-18 sc-6564 
Rab14 Santa Cruz rabbit H-55 sc-98610 




Rab35 Proteintech rabbit 11329-2-AP 
GST Abcam rabbit ab9085 
Homer 1 Syanptic Systems rabbit 160003 
 31	  
Chapter 3: A subset of SV proteins undergo activity-dependent degradation by the ESCRT 
pathway 
Rationale  
 The release of chemical neurotransmitter from synaptic vesicles (SVs) is essential for 
synaptic communication. In order for neurons to maintain rapid, efficient neurotransmission, SVs 
must undergo repeated cycles of fusion with the plasma membrane (exocytosis), followed by 
membrane retrieval (endocytosis) and vesicle reformation. These processes are mediated by a 
group of SV-associated proteins whose proper conformation and function are critical for synaptic 
health (see (Bezprozvanny and Hiesinger, 2013; Wang et al., 2013)). Indeed, without proper 
maintenance of SV pools, synapses become dysfunctional over time, leading to the loss of 
neuronal communication and ultimately to neurodegeneration (Garden and La Spada, 2008; Scott 
et al., 2010; Uytterhoeven et al., 2011). However, while the molecules that mediate SV 
exocytosis and endocytosis have been well characterized, very little is known about the 
molecular pathways responsible for SV protein turnover and degradation.  
In addition to its role in cellular homeostasis, protein degradation is also essential for 
synaptic plasticity and synapse formation/elimination, processes tightly linked to neuronal 
activity (see (Alvarez-Castelao and Schuman, 2015)). While the ability of neuronal activity to 
regulate postsynaptic protein degradation has been demonstrated (Ehlers, 2003; Lussier et al., 
2011; Schwarz et al., 2010; Scudder et al., 2014), few studies have examined the relationship 
between activity and presynaptic protein turnover. It has been reported that silencing neurons 
leads to the accumulation of presynaptic proteins (Lazarevic et al., 2011), suggesting that their 
turnover is slowed in the absence of activity; however, the direct effects of neuronal activity on 
SV protein degradation have not been investigated. In this chapter, we discover that the 
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degradation of a subset of SV proteins is regulated by neuronal activity. Further, we find that 
neuronal activity functions to recruit proteins of the ESCRT pathway to synapses to initiate 
endolysosomal degradation.  
Results 
SV integral membrane proteins turn over at different rates 
We first developed an assay to monitor the degradation of SV integral membrane proteins. A 
previous study used the protein synthesis inhibitor cycloheximide to monitor protein degradation 
in neurons (Sharma et al., 2011), and we tested this approach in hippocampal neurons cultured 
for 14 days in vitro (DIV), using DMSO (vehicle control) or cycloheximide (chx) to block 
protein synthesis for 24 or 36 hours. We performed immunostaining against Tau (axonal protein) 
and MAP2 (dendritic protein), and counterstained with the nuclear label DAPI to evaluate 
whether this long-term chx treatment caused neuronal toxicity, reflected by enlarged cell bodies, 
dendritic blebbing, axonal beading, and nuclear chromatin condensation (Figure 3.1A,B). We 
found that 36 hours of chx treatment led to one or more of these phenotypes in >60% of the 
fields of view scored, but that 24 hours of chx did not cause any detectable changes in neuronal 
health versus DMSO treatment alone (Figure 3.1A,B). Given this 24-hour chx treatment window, 
we next assessed whether it was possible to detect SV protein degradation during this time 
period. Lysates from neurons treated for 24 hours with DMSO or chx were collected and 
subjected to immunoblotting with antibodies against SV integral membrane proteins (VGLUT1, 
synaptophysin (Syp), SV2, synaptotagmin1 (Syt1), VAMP2) and the plasma membrane-
associated SNARE protein SNAP-25. Resulting immunoblots were imaged using the Odyssey 
Imaging System (LI-COR), which acquires images in the linear range without saturation or over-
exposure of protein bands, enabling very accurate quantification of protein levels. For each  
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protein, the fractional amount of degradation that occurred over 24 hours was expressed as a 
ratio of its intensity with chx treatment to its intensity with DMSO control treatment (c) (Figure 
3.1C,D), and normalized to tubulin. Since tubulin is a very stable protein, its levels were nearly 
always unchanged over the 24-hour time course. However, we found that the levels of SV2, Syt1, 
VAMP2 and SNAP-25 all decreased by approximately 20-35% within this time frame, while 
VGLUT1 and Syp levels were not significantly altered (Figure 3.1C,D). These findings indicate 
Figure 3.1: SV proteins exhibit different fractional amounts of degradation after protein synthesis inhibition. A) 
Representative images from 14 DIV neurons treated with DMSO or chx for 24 or 36 hours, immunostained with Tau 
antibodies to label axons (green), MAP2 antibodies to label dendrites (red), and mounted with DAPI to label nuclei 
(blue). Arrows in 36 hr panel denote the characteristics of cell health that were scored for B, including enlarged cell 
bodies, blebbing dendrites, and axonal beading. Note that Tau immunostaining becomes weaker following chx treatment 
due to protein synthesis inhibition. White scale bar=10µm. B) Quantification of cell health based on nuclear and process 
morphology (see Methods for details; n=5-7 fields of view/condition, *p<0.05, two-tailed t-test). C) Representative 
immunoblots of SV membrane proteins (VGLUT1, Synaptophysin (Syp), SV2, Synaptotagmin 1 (Syt 1), VAMP2) and 
the plasma membrane-associated SNAP-25, from lysates of 14 DIV neurons treated for 24 hours with either DMSO (c) 
or cycloheximide (chx). D) Quantification of protein intensity after 24 hrs chx treatment, normalized to tubulin and 
reported as a fraction of the DMSO control intensity (starting material). Averages are denoted by colored lines; each 
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that SV membrane proteins do not all turn over at the same rate, and therefore that SVs may not 
be degraded as discrete units. 
Neuronal activity stimulates the degradation of specific SV membrane proteins  
For those SV proteins whose levels were reduced following 24-hour chx treatment, we next 
evaluated whether their degradation was influenced by neuronal activity. Neurons were again 
treated for 24 hours with DMSO or cycloheximide, this time in the presence of commonly used 
pharmacological agents that either block neuronal activity (the Na+ channel blocker tetrodotoxin 
(TTX), the NMDA receptor blocker APV, and the AMPA receptor blocker CNQX), or increase 
activity (the GABA receptor antagonist bicuculline and the voltage-gated K+ channel blocker 4-
aminopyridine; Bic/4AP)(Ehlers, 2003; Tauskela et al., 2008; Wijayatunge et al., 2014). The 
efficacy of these agents was verified in 14 DIV neurons by recording and quantifying the 
frequency of spontaneous excitatory postsynaptic currents before and after drug application. We 
found that TTX, APV, and CNQX (blockers) significantly decreased this number, while Bic/4AP 
significantly increased it (Figure 3.2A,B). The amounts of protein degradation were expressed as 
“fold change in degradation vs. control” by dividing the activity conditions (blockers, Bic/4AP) 
by the DMSO control condition (see Chapter 2 for details). Faster protein degradation was 
expressed as an increase in fold change (>1), and slower degradation by a decrease in fold 
change (<1; Figure 3.2C-E). While the amounts of protein degradation were not significantly 
different between the DMSO control and blocker conditions (Figure 3.2C,E, Table 3.1), we 
found that Bic/4AP treatment significantly sped SV2 and VAMP2 degradation during the 24-
hour time course (by ~2-fold), but did not alter Syt1 or SNAP-25 degradation (Figure 3.2D,E). 
These interesting findings indicate that a subset of SV membrane proteins (VAMP2, SV2) is 
degraded in an activity-dependent manner. Such use-dependent turnover could be essential for 
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removing SV proteins that become damaged/misfolded through repeated cycles of SV 






Figure 3.2 - Neuronal activity drives the degradation of a subset of SV-associated proteins. A) 
Representative traces of 14 DIV neurons before and after application (indicated by black line) of 50µM 
AP5/10µM CNQX/0.5µM tetrodotoxin (blockers) to inhibit activity, or 40µM bicuculline/50µM 4-AP (bic/4AP) 
to stimulate activity. B) Quantification of spontaneous excitatory postsynaptic current frequency pre- and post-
treatment with blockers or bic/4AP. C) Representative immunoblots from 14 DIV neurons treated for 24 hours 
with DMSO (c) or chx in the presence of additional DMSO or blockers. Blots probed for SV2 and Syt1, or 
VAMP2 and SNAP-25, are shown with corresponding tubulin loading controls. D) Representative immunoblots 
from 14 DIV neurons treated for 24 hours with DMSO (c) or chx in the presence of additional DMSO or 
bic/4AP to stimulate neuronal activity, and probed for the same proteins as in C. E) Quantification of protein 
degradation in each condition, expressed as the fold change versus DMSO control. Treatments that speed protein 
degradation are represented by an increase in fold change (>1). Black dotted line denotes fractional degradation 
in the presence of DMSO control (black bar). For this and all subsequent bar graphs, mean ± SEM is shown, and 




Table 3.1 - Fractional protein degradation in a 24-hour period, based on neuronal activity 
levels.  
 
Protein DMSO APV/CNQX/TTX Bic/4AP 
VGLUT1 1.04 ± 0.08 N/A N/A 
Synaptophysin 0.98 ± 0.08 N/A N/A 
SV2 0.811± 0.029 0.854 ± 0.042 0.669 ± 0.026** 
VAMP2 0.813 ± 0.031 0.840 ± 0.047 0.647 ± 0.048** 
Synaptotagmin-1 0.691 ± 0.021 0.614 ± 0.012 0.657 ± 0.052 
SNAP-25 0.723 ± 0.042 0.732 ± 0.044 0.628 ± 0.076 
 
The fractional amount of degradation that occurred over 24 hours was expressed as a ratio of 
protein intensity with cycloheximide treatment to its intensity with DMSO control treatment. 
Numbers represent the average plus or minus the standard error of the mean. Student’s two-tailed 
t-tests were used to calculate significance of each experimental condition vs. DMSO control. 
Significantly different values are indicated (**=p<0.01).  
 
The ESCRT pathway is required for activity-dependent SV protein degradation 
To identify the cellular pathway responsible for activity-dependent degradation of SV2 and 
VAMP2, we initially focused on the ESCRT pathway. The ESCRT pathway comprises a series 
of protein complexes (ESCRT-0, -I, -II, -III, and Vps4) that catalyze the formation of MVBs and 
the sorting of cargo into MVBs for delivery to lysosomes (Raiborg and Stenmark, 2009). To 
confirm that this pathway has a role in SV protein degradation, as previously reported 
(Fernandes et al., 2014; Uytterhoeven et al., 2011), we examined the fold change in SV2 and 
VAMP2 degradation in the presence of an shRNA against the ESCRT-0 component Hrs (shHrs). 
Hrs, the initial component of the ESCRT-0 complex that binds and recruits ubiquitinated protein 
substrates, appears to be required for the initiation of MVB formation (see (Schmidt and Teis, 
2012)). When expressed between 7-14 DIV, we found that shHrs led to a 67.8+/-0.10% 
knockdown of Hrs protein (Figure 3.3A) without any observable toxicity. Further, shHrs 
significantly attenuated SV2 and VAMP2 degradation compared to scRNA control (Figure 
3.3B,C), indicating that basal degradation of these proteins occurs through the ESCRT pathway.  
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Figure 3.3 - The ESCRT pathway is required for basal and activity-dependent SV protein degradation. 
A) Representative immunoblots of Hrs, TSG101, and corresponding tubulin loading controls from 14 DIV 
neurons transduced with scRNA, shHrs, or shTSG101. Knockdown efficacy is 67.8+/-0.1% of scRNA control 
for shHrs, and 58.2+/-0.04% of control for shTSG101.  B) Immunoblots from 14 DIV neurons transduced with 
scRNA or shHrs, treated for 24 hours with DMSO (c) or chx, and probed for SV2, VAMP2 and tubulin. C) 
Quantification of the fold change in degradation of SV2 and VAMP2 compared to scRNA control (n=4; 
**=p<0.01). D) Immunoblots from 14 DIV neurons transduced with scRNA or shTSG101, treated for 24 hours 
with DMSO (c) or chx, and probed for SV2, VAMP2 and tubulin. E) Quantification of fold change in 
degradation of SV2 and VAMP2 compared to scRNA control (n=4; *=p<0.05). F) Immunoblots from 14 DIV 
neurons transduced with scRNA or shHrs and treated for 24 hours with DMSO (c) or chx in the presence of 
additional DMSO or bic/4AP, and probed for SV2, VAMP2 and tubulin. G) Quantification of fold change in 
degradation of SV2 and VAMP2 in the presence of scRNA or shHrs, +/- activity. DMSO control is set to 1 for 
each condition (scRNA black bars, shHrs blue bars), and bic/4AP treatment is expressed as fold change vs. 
DMSO control for that condition (n=6; *=p<0.05). 
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To bolster this finding, we repeated this experiment with an shRNA against TSG101, a 
component of the ESCRT-I complex that acts downstream of Hrs. Like shHrs, shTSG101 led to 
a relatively efficient 58.2+/-0.04% knockdown of TSG101 (Figure 3.3A) and attenuated SV2 and 
VAMP2 degradation (Figure 3.3D,E), indicating that the ESCRT pathway, and not just Hrs or 
the ESCRT-0 complex, facilitates the degradation of SV proteins. To assess whether this 
pathway also mediates the activity-dependent turnover of SV2 and VAMP2, neurons expressing 
scRNA or shHrs were treated with Bic/4AP or DMSO vehicle control, and changes in protein 
degradation measured after 24-hour chx treatment. We found that Bic/4AP treatment again 
increased the degradation of SV2 and VAMP2 by nearly two-fold in scRNA-expressing neurons 
(Figure 3.3F,G). In contrast, shHrs-expressing neurons exhibited no Bic/4AP-mediated increases 
in SV2 or VAMP2 degradation (Figure 3.3F,G). These findings indicate that the ESCRT 
pathway is essential for basal and activity-dependent turnover of these SV proteins. 
ESCRT proteins undergo activity-dependent recruitment to SV pools  
Although the ESCRT pathway has previously been linked to SV protein turnover (Fernandes et 
al., 2014; Uytterhoeven et al., 2011), the localization of ESCRT proteins in axons, and their 
behavior in response to neuronal activity, has not been investigated. Based on our findings, we 
hypothesized that ESCRT proteins would localize to axons and associate with SV pools, and that 
neuronal activity would increase this association. To test this concept, we transduced neurons 
with mCh-tagged Hrs (ESCRT-0 complex) or CHMP2B (ESCRT-III complex; MVB marker) on 
9 DIV, and treated neurons with either DMSO or Bic/4AP for 12 hours on 14 DIV. Neurons 
were then fixed and immunostained for VAMP2 to label SV pools. The percent colocalization of 
mCh-Hrs or CHMP2B-mCh puncta with VAMP2, and the number of puncta per unit length of 





approximately 40% of mCh-Hrs puncta colocalized with VAMP2 at baseline, treatment with 
Bic/4AP increased this value to nearly 75% (Figure 3.4AC). At the same time, increased 
neuronal activity led to nearly four times as many mCh-Hrs puncta/unit length axon compared to 
control neurons (Figure 3.4A,D). We also observed a striking change in the localization of 
CHMP2B-mCh following Bic/4AP treatment. In control neurons, CHMP2B-mCh puncta rarely 
appeared in axons. However, following Bic/4AP treatment, multiple CHMP2B-mCh puncta were 
present in axons, and ~35% of these colocalized with VAMP2 (Figure 3.4B,C). Together, these 
data show that neuronal activity dramatically increases the entry of ESCRT proteins into axons 
and their association with SV pools.  
To determine whether these SV pools were synaptic, and to examine the precise 
localization of the ESCRT proteins relative to SV pools, we performed high-resolution imaging 
of neurons transduced with mCh-Hrs or CHMP2B-mCh, treated with Bic/4AP, and 
immunostained with VAMP2 and the postsynaptic protein Homer1. Hrs and CHMP2B puncta 
associated with both synaptic and non-synaptic VAMP2 clusters, with nearly twice as many 
Figure 3.4 - Neuronal activity recruits ESCRT proteins to synaptic vesicle pools. 
A) Images of neurons transduced with mCh-Hrs, treated with DMSO or bic/4AP for 12 hours, then fixed and 
immunostained against VAMP2 (green) and Tau (blue). Arrows represent VAMP2 puncta that colocalize with 
mCh-Hrs in axons. Scale bar=10µm. B) Images of neurons transduced with CHMP2B-mCh, treated with DMSO 
or bic/4AP for 12 hours, then fixed and immunostained against VAMP2 (green) and Tau (blue). Arrows 
represent VAMP2 puncta that colocalize with CHMP2B-mCh in axons. Scale bar=10mm. C) Quantification of 
the fraction of Hrs or CHMP2B puncta colocalized with VAMP2 (For Hrs: n=4 DMSO, n=8 bic/4AP from 3 
replicate weeks, ~30 puncta/image; *=p<0.05. For CHMP2B: n=5 for DMSO, n=8 for bic/4AP from 2 replicate 
weeks, ~10 puncta/image; **=p<0.01). D) Quantification of the number of Hrs puncta per unit length of axon 
(arbitrary units; n=4 DMSO, n=5 bic/4AP, *=p<0.05, ~30 puncta/image, similar results obtained for 3 
independent experiments). E) Super-resolution images of neurons transduced with mCh-Hrs, treated as in A and 
immunostained against VAMP2 and Homer1. Arrowhead indicates non-synaptic mCh-Hrs puncta, and arrows 
indicate synaptic puncta based on colocalization with Homer1. Inset shows higher magnification view of a 
synaptic site. F) Super-resolution images of neurons transduced with CHMP2B-mCh, treated as in A and 
immunostained against VAMP2 and Homer1. Arrowheads indicate non-synaptic CHMP2B-mCh puncta and 
arrows indicate synaptic puncta. Inset shows higher magnification view of a synaptic site. Scale bar=5µm, 2.5µm 
for inset. G) Quantification of the synaptic and non-synaptic fractions of Hrs and CHMP2B puncta in axons 
following neuronal activity (~200 puncta for Hrs, ~120 puncta for CHMP2B). 
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puncta at synaptic clusters based on their colocalization with Homer1 (67% synaptic vs. 33% 
non-synaptic for Hrs, 68% synaptic vs. 32% non-synaptic for CHMP2B; Figure 3.4E-G). 
Moreover, Hrs and CHMP2B puncta typically exhibited partial but not complete overlap with 
VAMP2 clusters (Figure 3.4E,F), suggesting that they could represent distinct vesicle 
populations or associate with subsets of SVs.  
 To further characterize the effect of neuronal activity on the localization of the ESCRT 
pathway, we performed live imaging of mCh-Hrs following activity treatment in microfluidic 
chambers. The use of these chambers allowed us to preferentially examine Hrs movement within 
axons and eased the ability to discern the directionality of these movements. We recorded time 
lapse movies of mCh-Hrs movement every 5 seconds for 50 frames. First, we generated 
kymographs in which a stationary particle appears as a straight line while anterograde or 
retrograde movements appear as diagonal lines to the left or right, respectively (Figure 3.5A). In 
DMSO treated neurons, Hrs puncta were primarily stationary with very few anterograde or 
retrograde events, whereas in Bic/4AP treated neurons, the majority of particles show movement 
in one or both directions (Figure 3.5A). Quantification of these events revealed that 
approximately 20% of Hrs puncta in DMSO treated neurons could be classified as ‘moving’, 
defined as showing any movement in >45% of the frames. As early as 1 hour after Bic/4AP 
treatment, a significant increase was observed, wherein nearly 70% of puncta were moving 
(Figure 3.5B). We next examined the directionality of the moving puncta, classifying their 
movement as primarily anterograde or retrograde, based on movement in the given direction for 
>45% of the frames, or as bidirectional. We found a trend towards increased retrograde 
movement (p=0.07), and a similar trend for increased bidirectional movement (p=0.055), though 
these values did not reach significance (Figure 3.5C). Additionally, the average velocity of all 
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Hrs puncta increased nearly 4 fold following treatment with Bic/4AP (Figure 3.5D). These 
results show that neuronal activity serves as cue to initiate Hrs transport within axons. Further 
work examining the dynamics of Hrs movement over an expanded timeframe of activity 
treatment, along with an examination of the co-trafficking of SV proteins over this timeframe, 
will be necessary to elucidate the activity-dependent changes in ESCRT-mediated SV trafficking.  
 
Figure 3.5 - Neuronal activity changes Hrs trafficking dynamics.  
A) Representative kymographs of mCh-Hrs puncta from 10 DIV neurons treated with DMSO or Bic/4AP for 1 
hour prior to imaging. Images were acquired every 5 seconds over an approximately four-minute time course. B) 
Quantification of stationary vs. moving mCh-Hrs puncta based on their behavior in >45% of the frames in each 
condition. Significantly more puncta were moving in neurons treated with Bic/4AP vs. DMSO control 
(**=p<0.01, n=5-6 neurons.50 frames each). C) Quantification of the directionality of moving mCh-Hrs puncta. 
A trend towards increased retrograde (p=0.07) and bidirectional (p=0.055) movement was observed in neurons 
treated with Bic/4AP (n=5-6 neurons). Quantification of the average velocity of mCh-Hrs puncta in each 
condition. mCh-Hrs puncta in neurons treated with Bic/4AP moved three-fold faster on average (**=p<0.01, 
n=5-6 neurons).   
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We next attempted to directly address the question of whether neuronal activity drives 
MVB formation at synapses by performing electron microscopy. Neurons were treated for 12 
hours with Bic/4AP or DMSO, then fixed, sectioned, stained and subjected to electron 
microscopy. Though MVBs have been identified in axons and presynaptic compartments, these 
MVBs have very diverse morphologies (Altick et al., 2009; Kadota et al., 1994; Von Bartheld 
and Altick, 2011) and have primarily been characterized in motor neurons and neuromuscular 
junctions, not small central synapses. Thus, while we see a number of MVB-like structures that 
may represent distinct types of MVBs, or MVBs at different stages of formation (Figure 3.6A,B), 
we cannot definitively categorize them as MVBs. Further characterization of these structures in 
conjunction with MVB marker labeling or 3D reconstruction will be necessary to determine 
whether neuronal activity drives their formation.  
 
Figure 3.6 - Ultrastructural analysis of presynaptic boutons 
A-B) EM micrographs of presynaptic boutons from 14 DIV neurons treated with Bic/4AP for 12 hours. Multiple 
endosomal structures can be seen, potentially representing sorting/recycling endosomes or MVBs at various 
stages of maturation (arrows; A). B) A large (200 nm) vesicular structure potentially representing an MVB 




In this chapter, we find that a subset of SV proteins, SV2 and VAMP2, undergo activity-
dependent degradation. Furthermore, we show that the degradation of these proteins relies on the 
ESCRT pathway, suggesting that they are sorted from an early endosomal structure, packaged 
into MVBs, and transported to the lysosome for degradation. Finally, we find that neuronal 
activity functions to recruit proteins of the ESCRT pathway into axons and specifically to pools 
of synaptic vesicles, suggesting that the initiation of degradation occurs locally at these sites.  
Mechanisms of SV protein turnover   
Mechanisms of SV protein degradation are poorly understood, and our study is among the first to 
investigate them. For instance, the fundamental question of whether SV membrane proteins turn 
over individually or as a group has not been resolved. In our cycloheximide assays, we observed 
that some membrane proteins (i.e. VGLUT1, synaptophysin) were long-lived, showing no 
significant change within the 24-hour time course, while others (i.e. SV2, synaptotagmin1) 
underwent a ~35% reduction compared to starting material. Another recent study that utilized 
SILAC and proteomics to measure synaptic protein turnover also found variation in the basal 
half-lives of different SV proteins, and calculated these half-lives to be on the order of 1-4 days, 
or ~2-40 molecules per hour per synapse (Cohen et al., 2013). Together, these findings indicate 
that SV protein turnover occurs through the regulated degradation of specific proteins as opposed 
to the degradation of entire SVs. They also demonstrate that SV protein degradation is an active, 
ongoing process, in contrast to earlier reports that estimated SV protein turnover to be extremely 
slow, with half-lives on the order of 20 days (Morris et al., 1971).   
  We also observed variability in the dependence of SV-associated protein degradation on 
neuronal activity, with SV2 and VAMP degradation increased by activity and Synaptotagmin1 
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and SNAP-25 degradation unchanged. Why this variability occurs remains an open question. 
One possibility is that cellular surveillance mechanisms (i.e. molecular chaperones, 
ubiquitinating enzymes) are coupled to activity in order to efficiently remove reactive or 
structurally complex proteins that are susceptible to damage from continuous SV recycling. 
VAMP2 and SV2 may have structural motifs that are particularly vulnerable to misfolding or 
oxidation. Alternatively, the specific functions of these proteins (i.e. VAMP2 as the primary v-
SNARE in the brain, SV2 as a chaperone for Synaptotagmin1 (Zhang et al., 2015) may require 
particularly vigilant control mechanisms that are tightly linked to neuronal activity. Interestingly, 
several groups have shown that specific postsynaptic proteins are ubiquitinated and degraded in 
an activity-dependent manner while others are not (Ehlers, 2003; Lussier et al., 2011; Schwarz et 
al., 2010). Moreover, the ubiquitinating enzymes responsible for the ubiquitination/degradation 
of postsynaptic glutamate receptors are regulated by neuronal activity (Scudder et al., 2014), and 
such a mechanism could also link activity with SV2 or VAMP2 ubiquitination and degradation. 
An intriguing possibility is that they accumulate ubiquitin moieties through cycles of exo- and 
endocytosis, and that these cumulative linkages target heavily-used SV proteins for degradation. 
However, the identities of the ubiquitinating enzymes responsible for this activity, the signals 
that regulate these enzymes, and the specific SV proteins that are ubiquitinated in response to 
activity remain largely unknown and will be investigated in Chapter 5.  
ESCRT pathway in SV protein homeostasis 
Our studies show that the ESCRT pathway is responsible for the basal and activity-dependent 
turnover of SV2 and VAMP2. This finding lends further support to the growing evidence of the 
importance of endosomes in the SV life cycle. Our study implicating the ESCRT pathway as an 
essential component of SV protein degradation points to a role of endosomes in the removal of 
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dysfunctional or damaged proteins. Indeed, studies in Drosophila have also identified 
components of the ESCRT pathway as essential in preserving a healthy and functional readily 
releasable pool of SVs (Fernandes et al., 2014; Uytterhoeven et al., 2011). Together with our 
studies, these findings suggest that maintaining SV protein homeostasis is crucial to retaining 
proper neuronal communication and thus neuronal health, an idea we will further explore in 
Chapter 5.  
 One of the most interesting aspects of our findings is that neuronal activity functions as a 
cue to initiate ESCRT dependent degradation of SV2 and VAMP2 at synapses. Although we 
cannot conclude that MVBs form at the synapse, our data do suggest that ESCRT components 
are recruited to synapses in response to increases in neuronal activity. While these studies do not 
preclude the involvement of macroautophagy in presynaptic protein degradation, they do offer an 
intriguing possibility that different degradative pathways may be activated in response to specific 
signals. Perhaps neuronal activity activates certain proteins or signaling cascades that specifically 
interact with ESCRT proteins and lead to their synaptic recruitment. This idea will be further 










Chapter 4: Rab35 regulates activity-dependent degradation of SV2 and VAMP2 through 
its effector, Hrs 
Rationale 
In the previous chapter, we discovered that specific SV proteins are degraded in a use-dependent 
manner that relies on the ESCRT pathway. Further, we found that proteins of the ESCRT 
pathway are recruited into axons and to synaptic vesicle pools by neuronal activity. In this 
chapter, we investigate how this striking axonal recruitment of ESCRT proteins occurs. Based on 
their key roles in trafficking proteins into the endocytic pathway (Stenmark, 2009), we 
hypothesized that Rab GTPases might play a role in this process. More than half of the 60 
mammalian Rabs can be co-purified with SV pools (Pavlos and Jahn, 2011; Takamori et al., 
2006), and several of these (Rabs 5, 10, 14, 21, 35) associate with early and recycling endosomes 
in neurons and other cell types (Babbey et al., 2006; Fischer von Mollard et al., 1994; Junutula et 
al., 2004; Pavlos and Jahn, 2011; Sato et al., 2008; Uytterhoeven et al., 2011). Given their 
putative and reported roles in the endocytic pathway, we hypothesized that one or more of these 
would mediate SV protein degradation. Moreover, Hrs also localizes to early endosomes 
(Komada and Soriano, 1999; Sato et al., 2008) and is the initial component of the ESCRT 
pathway, leading us to further hypothesize that it could interact with one or more of the 
endocytic Rabs to mediate SV protein degradation.  
Results        
Rab35 interacts with Hrs and stimulates SV protein degradation 
To test for Hrs/Rab interactions, we performed co-immunoprecipitation assays in HEK293T cells 
expressing Flag-Hrs and HA-tagged Rabs 5, 10, 14, 21, or 35. Interestingly, we found that Rabs 
10, 14, and 35 were efficiently co-immunoprecipitated by Flag-Hrs, while Rabs 5 and 21 were  
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Figure 4.1 - A subset of endocytic Rabs interact with Hrs and/or drive SV protein degradation. 
A) Immunoblot of HEK cell lysates expressing HA-Rab5, 10, 14, 21 or 35 and Flag-Hrs, subject to IP with Flag 
antibody and probed with HA or Flag antibodies. B) Quantification of HA-Rab intensity in the eluate, normalized 
to input intensity and Flag-Hrs intensity in the eluate (n=3, **p<0.01). C) Representative images from 14 DIV 
neurons transduced with mCh-tagged Rab3, Rab5, Rab10, Rab14, or Rab35 and immunostained with VAMP2 
antibodies. Arrows represent VAMP2 puncta (green) in axons expressing mCh-Rab (purple). Scale bar=10 µm. D) 
Immunoblots from 14 DIV neurons transduced with mCh-tagged Rab3, Rab5, Rab10, Rab14, or Rab35, and 
probed for the respective Rab. E) Quantification of mCh-tagged Rab intensity, expressed as fold change vs. 
endogenous Rab level (n=3). F) Immunoblots from 14 DIV neurons untransduced or transduced with mCh-Rab3, 
treated for 24 hrs with either DMSO (c) or chx, and probed for SV2 or VAMP2 and tubulin. G) Quantification of 
SV2 or VAMP2 intensity from each condition, normalized as in Figure 3.1, showing that Rab3 overexpression 
does not speed SV2 protein degradation (n=3). 
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not (Figure 4.1A,B). These findings demonstrate that a subset of endocytic Rabs interact with 
Hrs, and may participate in SV protein degradation.  
We next tested whether overexpression of any of these endocytic Rabs could stimulate 
SV2 and VAMP2 degradation in hippocampal neurons. Multiple groups have reported that 
overexpression of wild-type small GTPases induces phenotypes that reflect their activation 
(Brondyk et al., 1993; Li and Stahl, 1993; McCaffrey et al., 2001; Ravikumar et al., 2008).  
Furthermore, it was recently demonstrated that the conventional ‘constitutively-active’ mutants 
are not active for all Rabs, including Rab35 (Langemeyer et al., 2014). We therefore used wild-
type rather than constitutively-active Rabs for our studies, anticipating that their relatively 
modest overexpression by lentivirus would lead to phenotypes reflecting their activated states, 
while at the same time minimizing the toxicity often associated with Rab overexpression (Star et 
al., 2005). Indeed, when neurons were transduced with mCherry-tagged Rabs (5, 10, 14, or 35) 
for four days prior to cycloheximide-chase experiments, we found that they localized to axons 
and presynaptic boutons, and were overexpressed to similar degrees (Figure 4.1C-E) with no 
observable toxicity. Lysates from Rab-expressing neurons were collected and immunoblotted for 
SV2 and VAMP2, and the fold change in protein degradation calculated for each Rab. Rab3, an 
SV-associated Rab with a well-characterized role in SV exocytosis (Pavlos and Jahn, 2011; Yu 
et al., 2008), served as our control in these studies as its overexpression did not alter SV protein 
degradation compared to untransduced neurons (Figure 4.1F,G).  Similarly, we found that Rabs 
10 and 14 did not alter SV2 or VAMP2 degradation over the 24-hour period (Figure 4.2A,B). In 
contrast, overexpression of Rabs 5 and 35 increased the amount of SV2 and VAMP2 degradation 
by greater than two-fold (Figure 4.2A,B). Both of these Rabs were previously reported to have 
roles in SV recycling (Shimizu et al., 2003; Uytterhoeven et al., 2011; Wucherpfennig et al., 
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2003) and Rab35 was recently implicated in the turnover/replenishment of SV proteins at the 
Drosophila neuromuscular junction (Fernandes et al., 2014; Uytterhoeven et al., 2011). However, 
as Rab35 interacts with Hrs and Rab5 does not (Figure 4.1A,B), we investigated the specificity 
of these Rabs for SV integral membrane protein degradation. We found that Rab5 
overexpression sped the degradation of several presynaptic proteins, including SNAP-25 (a 
plasma membrane-associated protein) and Munc13 (an active zone protein), while Rab35 only 
sped the degradation of SV2 and VAMP2 (Figure 4.2C,D). These findings suggest that the 
Rab35/Hrs interaction is important for defining the specificity of the degradative pathway for SV 
integral membrane proteins.  
Since the degradation of SV proteins and membranes has been reported to occur via 
lysosomes (Fernandes et al., 2014; Haberman et al., 2012; Tian et al., 2015), we assessed 
whether Rab35-mediated protein degradation required this organelle. Rab35-expressing neurons 
were treated with proteasome or lysosome inhibitors (200 nM epoxomicin or 100 mM 
chloroquine/leupeptin, respectively) for the last 18 hours of their 24-hour incubation with 
cycloheximide.  As anticipated, we found that Rab35-mediated degradation of SV2 and VAMP2 
was completely unaffected by epoxomicin, but significantly attenuated by chloroquine/leupeptin 
(Figure 4.2E-F), demonstrating that Rab35 acts in a lysosome-dependent degradative pathway.  
 
 We next wanted to determine whether Rab35-mediated SV protein degradation targeted 
the synaptic/axonal pool of proteins. To do this, we measured the levels of presynaptic/axonal 
VAMP2 by quantitative immunofluorescence microscopy.  We compared the steady-state levels 
and the levels of VAMP2 remaining after 24 hours of chx treatment in axons from 14 DIV 
neurons expressing mCh-Rab35 versus mCh-Rab3 control. Average fluorescence intensities of 
VAMP2 puncta in axons expressing Rab3 or Rab35 were quantified and presented as a fraction  
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Figure 4.2 - A subset of endocytic Rabs drive SV protein degradation. 
A) Immunoblots from 14 DIV neurons transduced with mCh-tagged Rab3, Rab5, Rab10, Rab14, or Rab35, 
treated for 24 hrs with either DMSO (c) or chx, and probed for SV2, VAMP2 and tubulin. B) Quantification of 
the fold change in degradation of SV2 and VAMP2 for each Rab vs. Rab3 control (n=3-4 independent 
experiments, *=p<0.05). C) Immunoblots from 14 DIV neurons transduced with mCh-Rab3, -Rab5, or -Rab35, 
treated for 24 hours with DMSO (c) or chx and probed for SNAP-25, Munc-13, and tubulin. D) Quantification of 
the fold change in degradation of SNAP-25 and Munc-13 intensity for each Rab vs. Rab3 control (n=3; 
*=p<0.05). E) Immunoblots from 14 DIV neurons transduced with mCh-Rab35, treated for 24 hours with 
DMSO (c) or chx, and further incubated with DMSO vehicle (Rab35), 200 nM epoxomycin (+Epox), or 100 mm 
chloroquine and 100 mm leupeptin (+CL) for 18 hours. Blots were probed for SV2, VAMP2 and tubulin. F) 
Quantification of the fold change in degradation of SV2 and VAMP2 from each condition (n=3; **=p<0.01). 
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of the average intensity in Rab3-expressing axons. We found that the steady-state levels of 
VAMP2 puncta were not significantly different between Rab3 and Rab35-expressing neurons 
(Figure 4.2A,B), indicating that this assay was not sensitive enough to detect subtle changes in 
VAMP2 steady-state levels. However, similar to our immunoblot experiments, we found that 
VAMP2 levels were significantly lower 24 hours after chx treatment in axons expressing Rab35 
compared to those expressing Rab3 (Figure 4.2A,B). To further confirm these findings, we used 
the SNAP-tag system for quantitative fluorescence pulse-chase analysis (Bodor et al., 2012). The 
SNAP-tag is a self-labeling enzyme that allows for covalent attachment of an exogenously 
applied fluorescent compound to a protein of interest. We designed a dual SNAP- and Flag-
tagged VAMP2, which was co-expressed in neurons with either mCh-Rab3 or mCh-Rab35. On 
13 DIV, neurons were incubated for 30 minutes with the SNAP-tag substrate benzylguanine-
Oregon Green (BG-OG, New England Biolabs), washed, and then returned to normal media. 
Neurons were subsequently fixed at two time points after labeling (15 and 48 hrs) and 
immunostained with anti-Flag antibody, allowing us to measure both the “pulsed” fraction of 
VAMP2-SNAP (via BG-OG intensity) and the total pool of VAMP2-SNAP (via Flag intensity) 
present at each time. After 15 hours, we saw no significant differences in the intensity of BG-OG 
labeling, the intensity of Flag immunostaining, or the colocalization of BG-OG with Flag 
immunostaining in Rab3 versus Rab35-expressing neurons, though there was a trend towards 
decreased BG-OG/Flag colocalization in Rab35-expressing neurons (Figure 4.3C,D). These 
results indicate that Rab35 expression does not lead to lower levels of VAMP2-SNAP expression 
or initial BG-OG labeling. However, after 48 hours, both the intensity of BG-OG labeling and 
the colocalization of BG-OG with Flag immunostaining were significantly reduced in Rab35-
expressing neurons compared to Rab3 controls, while total VAMP2-SNAP levels were not 	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altered (Figure 4.3C,E). These data confirm that Rab35 stimulates degradation of the synaptic 
pool of SV proteins.  
 54	  
Rab35 is necessary for activity-dependent SV protein degradation upstream of the ESCRT 
pathway  
Our data so far demonstrate that Rab35 overexpression is sufficient to drive SV2 and VAMP2 
degradation via lysosomes. To determine if Rab35 is also necessary for the degradation of SV 
membrane proteins, we again utilized 24-hour cycloheximide treatment in conjunction with 
quantitative immunoblotting and immunofluorescence microscopy, this time in neurons 
expressing an shRNA against Rab35 (shRab35). This published shRNA (Allaire et al., 2010) 
efficiently reduced Rab35 protein levels by ~65% (Figure 4.4A). We first performed functional 
imaging studies in neurons co-expressing shRab35 and super-ecliptic pHluorin (SEP)-tagged 
synaptophysin, and found that knockdown of Rab35 between 3-14 DIV did not affect neuronal 
health, the ability of SVs to undergo exo/endocytosis, or the size of the total recycling pool of 
SVs (Figure 4.4B,C). Using the same time course as in previous experiments, we found that 
shRab35 significantly attenuated the degradation of SV2 and VAMP2 (by ~15%) compared to a 
scrambled control shRNA (scRNA), and did not alter the degradation of SNAP-25 or the active  
zone protein RIM1a (Figure 4.4D,E). Co-expression of shRNA-resistant Rab35 rescued this  
Figure 4.3 - Rab35 drives SV protein degradation at synapses.  
A) Representative images from 14 DIV neurons transduced with either mCh-Rab3 or -Rab35, treated for 24 
hours with DMSO or chx and immunostained with VAMP2 antibodies. Arrows represent VAMP2 puncta 
(green) in axons expressing mCh-Rab3 or mCh-Rab35 (purple). Scale bar=10 µm. B) Quantification of the 
average fluorescence intensity of VAMP2 puncta, normalized to Rab3 (n=9 images/condition; 3 replicate weeks, 
each with 3 images/condition, ~100 puncta/image; *=p<0.05). C) Representative images from neurons 
expressing VAMP2-SNAP and either mCh-Rab3 or mCh-Rab35, fixed 15 or 48 hours after BG-Oregon Green 
(BG-OG) labeling and immunostained with Flag antibodies. Arrows represent VAMP2 puncta detected with 
Flag (blue) in axons expressing mCh-Rab3 or mCh-Rab35 (red). Scale bar=10 µm. D) Quantification of the 
average fluorescence intensity of Flag staining (n=5; ~100 puncta/image), BG-OG labeling (n=10; ~100 
puncta/image), and the fraction of BG-OG puncta that colocalize with Flag (n=6 for Rab3, n=5 for Rab35; ~75 
puncta/image) in each condition normalized to Rab3 at the 15 hour time point. Student’s two-tailed t-tests with a 
hypothetical value of 1.0 were performed. E) Quantification as in D for Flag staining (n=5; ~100 puncta/image), 
BG-OG labeling (n=7 images/condition; ~100 puncta/image; similar results obtained for 3 independent 
experiments; **=p<0.01), and BG-OG puncta colocalization (n=19 images/condition from 3 replicate weeks, 
~75 puncta/image; **=p<0.01) for the 48 hour time point.  
	  
 55	  
Figure 4.4 - Rab35 is necessary for SV membrane protein degradation 
A) Immunoblot from 14 DIV neurons transduced with scRNA or shRab35 and probed for Rab35 and tubulin. 
Knockdown efficacy of Rab35 is 64.7+/-0.04% of scRNA control.  B) Sample traces of synaptophysin-SEP 
fluorescence from 14 DIV neurons co-transfected with scRNA or shRab35 and synaptophysin-SEP, expressed as 
change in initial fluorescence over time. Images were acquired every 5 seconds before, during (black bar), and after 
 56	  
10 Hz, 30 seconds stimulation to elicit SV exo/endocytosis, as described in supplemental methods (n=3 
experiments/condition). C) Quantification of the size of the recycling pool of synaptic vesicles in scRNA and 
shRab35-expressing neurons, measured as the fraction of peak fluorescence intensity of synaptophysin-SEP during 
stimulation (at ~t=50 sec in B) versus its intensity following deacidification with NH4Cl to visualize the entire SV 
pool. Values are normalized to scRNA control (n≥13). D) Immunoblots from 14 DIV neurons transduced with 
scRNA or shRab35, treated for 24 hours with DMSO (c) or chx and probed for SV2, VAMP2, SNAP-25, Rim1a and 
tubulin. Several immunoblots represent the same experiment and therefore have the same tubulin image. E) 
Quantification of the fold change in degradation of SV2, VAMP2, SNAP-25, and Rim1a for each condition (n=3-4, 
*=p<0.05). F) Immunoblots from 14 DIV neurons transduced with scRNA, shRab35, or shRab35+sh-resistant 
Rab35 (rRab35) treated for 24 hours with either DMSO (c) or cycloheximide (chx) and probed for SV2, VAMP2 
and tubulin. G) Quantification of the fold change in degradation of SV2 and VAMP2 for shRab35 vs. scRNA 
control (n=4, *=p<0.05).	  
	  
attenuation of SV protein degradation by shRab35 (Figure 4.4F,G). Together, these results 
demonstrate that Rab35 is both sufficient and necessary for the degradation of SV integral 
membrane proteins.    
We subsequently examined whether Rab35 was necessary for activity-dependent SV 
protein degradation. As in the previous chapter, neurons expressing scRNA and shRab35 were 
treated with Bic/4AP to increase activity, and protein degradation was monitored after 24-hour 
chx treatment. Remarkably, we found that the ability of Bic/4AP to stimulate SV2 and VAMP2 
degradation was nearly abolished in neurons expressing shRab35 (Figure 4.5A,B). Furthermore, 
Rab35 does not stimulate SV protein degradation by increasing neuronal activity, as blocking 
activity in Rab35-expressing neurons did not significantly alter the degradation of SV2 and 
VAMP2 compared to Rab35 overexpression alone (Figure 4.5C,D). These findings demonstrate 
that activity-dependent SV protein turnover is dependent on Rab35.  
 To determine if Rab35 acts upstream of the ESCRT pathway, we measured the 
degradation of SV2 and VAMP2 in neurons co-expressing scRNA or shHrs and mCh-Rab35. As 
anticipated, Rab35-mediated degradation of SV2 and VAMP2 was significantly attenuated in 
shHrs-expressing neurons (Figure 4.6A,B). Moreover, average VAMP2 immunofluorescence 
intensity was increased by 40% in the presence of shHrs/mCh-Rab35 vs. scRNA/mCh-Rab35 
(Figure 4.6C,D). We also performed these experiments in neurons expressing mCh-Rab35 and 
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scRNA or shTSG101 and found similar results by immunoblotting and quantitative 
immunofluorescence (Figure 4.6E-H). Together, these data demonstrate that Rab35 acts 
upstream of the ESCRT pathway to mediate degradation of SV proteins. 
 
Figure 4.5 - Knockdown of Rab35 inhibits activity-dependent SV protein degradation. 
A) Immunoblots from 14 DIV neurons transduced with scRNA or shRab35 and treated for 24 hours with DMSO 
(c) or chx in the presence of additional DMSO or bic/4AP, and probed for SV2, VAMP2 and tubulin. B) 
Quantification of fold change in degradation of SV2 and VAMP2 in the presence of scRNA or shRab35, +/- 
activity. As in Fig. 3.3, DMSO control is set to 1 for each condition (scRNA black bars, shRab35 red bars), and 
bic/4AP treatment is expressed as fold change vs. DMSO control for that condition (n=8; *=p<0.05). C) 
Immunoblots from 14 DIV neurons transduced with mCh-Rab35 and treated for 24 hours with DMSO (c) or chx 
in the presence of additional DMSO or APV/CNQX/TTX to inhibit neuronal activity (blockers). Blots were 
probed for SV2, VAMP2 and tubulin. D) Quantification of the fold change in degradation of SV2 and VAMP2 





Hrs is an effector of Rab35 
Our co-immunoprecipitation experiments demonstrated an interaction between Rab35 and Hrs 
(Figure 4.1A,B). To further characterize the specificity of this interaction, we co-expressed 
EGFP-Rab35 together with a series of mCh-tagged ESCRT proteins in HEK293T cells. We 
found that EGFP-Rab35 robustly co-localized with Hrs, but not with TSG101 or CHMP2B 
(Figure 4.7A). Next, we performed co-immunoprecipitation assays in HEK293T cells expressing 
HA-Rab35 together with a similar series of mCh-tagged ESCRT proteins. HA-Rab35 co-
precipitated with Hrs, but not with STAM (another ESCRT-0 component), TSG101, or 
CHMP2B (Figure 4.7B). Given the specificity of the Rab35-Hrs interaction, we next investigated 
whether Hrs was a direct effector of Rab35. Effectors are recruited by active (GTP-bound) Rabs 
to carry out the relevant downstream vesicle sorting, uncoating, trafficking, tethering, or fusion 
steps (Stenmark, 2009) Here, we performed co-immunoprecipitation assays in HEK cell lysates 
expressing HA-Rab35 and Flag-Hrs, and subsequently incubated with either GDP or GTPγS. We 
observed that significantly more HA-Rab35 was co-precipitated by Flag-Hrs in the presence of 
GTPγS than GDP, as expected if Hrs is a Rab35 effector (Figure 4.7C,D). To confirm these 
findings, we performed pull-down experiments with GST-Rab loaded with GDP or GTPγS, 
Figure 4.6 - The ESCRT pathway functions downstream of Rab35 to mediate SV protein degradation.  
A) Immunoblots from 14 DIV neurons transduced with mCh-Rab35 and either scRNA or shHrs, treated for 24 
hours with DMSO (c) or chx and probed for SV2, VAMP2 and tubulin. B) Quantification of the fold change in 
degradation of SV2 and VAMP2 for Rab35/shHrs vs. Rab35/scRNA control (n=3; **=p<0.01). C) Images from 
14 DIV neurons transduced with mCh-Rab35 and either scRNA or shHrs, fixed 24 hours after chx treatment, and 
immunostained against VAMP2. Arrows represent VAMP2 puncta in axons expressing Rab35 and either scRNA 
or shHrs. Scale bar=10 µm. D) Quantification of the average fluorescence intensity of VAMP2 puncta, 
normalized to Rab35 + scRNA control (n=6 images/condition from 2 replicate weeks, ~100 puncta/image; 
**=p<0.01). E) Immunoblots from 14 DIV neurons transduced with mCh-Rab35 and either scRNA or 
shTSG101, treated for 24 hours with DMSO (c) or chx and probed for SV2, VAMP2 and tubulin. F) 
Quantification of the fold change in degradation of SV2 and VAMP2 for Rab35/shTSG vs. Rab35/scRNA (n=3, 
*=p<0.05). G) Images from 14 DIV neurons transduced with mCh-Rab35 and either scRNA or shTSG101, fixed 
24 hours after chx treatment and immunostained against VAMP2. Arrows represent VAMP2 puncta in axons 
expressing Rab35 and either scRNA or shTSG101. Scale bar=10 µm. H) Quantification of the average 
fluorescence intensity of VAMP2 puncta, normalized to Rab35 + scRNA control (n=3 images/condition, ~100 
puncta/image, similar results obtained for 2 independent experiments; *=p<0.05). 
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coupled to glutathione-agarose beads, and incubated with HEK cell lysate expressing Flag-Hrs. 
We again found that GST-Rab35-GTP pulled down significantly more Flag-Hrs (Figure 4.7E,F),  
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consistent with the co-immunoprecipitation results. Thus, our data clearly show that Hrs is an 
effector of Rab35, providing a direct mechanistic link between Rab35 and the ESCRT pathway.  
 Based on this finding, we hypothesized that Rab35 would recruit Hrs to SV pools in order 
to initiate ESCRT complex formation. Since the available antibodies against Rab35 and Hrs are 
not suitable for immunofluorescence microscopy in neurons, we tested this prediction by co-
transfecting neurons with mCh-Hrs and either soluble EGFP or EGFP-Rab35. Neurons were 
subsequently fixed and immunostained for VAMP2, and the percent colocalization of mCh-Hrs 
puncta with VAMP2 puncta was quantified and compared in the presence or absence of EGFP-
Rab35. We found that while approximately 40% of mCh-Hrs puncta colocalized with VAMP2 at 
baseline, co-expression of EGFP-Rab35 increased this value to nearly 70% (Figure 4.8A,C), 
similar to neuronal activity (Figure 3.4A,C). These data confirm that Rab35 is able to effectively 
recruit Hrs to SV pools in axons. Similar results were seen with CHMP2B (Figure 4.8B,C), 
suggesting that Rab35 recruits Hrs to initiate formation of MVBs in axons. 
To better visualize the spatial relationship between Rab35 and ESCRT pathway proteins in axons, 
we acquired super-resolution images of neurons co-transfected with EGFP-Rab35 and mCh-Hrs 
or CHMP2B-mCh. EGFP-Rab35 was observed along axons in small puncta and, more rarely, 
enlarged endosomal structures (Figure 4.8D,E), on which we focused in order to resolve the 
spatial distribution of Rab35 and the ESCRT proteins. EGFP-Rab35 and mCh-Hrs exhibited a 
high degree of colocalization on these enlarged endosomes (Figure 4.8D), indicating that they  
Figure 4.7 - ESCRT-0 component Hrs is an effector of Rab35.  
A) Images of HEK293T cells co-expressing EGFP-Rab35 and the indicated mCh-tagged ESCRT proteins. Scale 
bar=10 µm. B) Immunoblot of lysates from HEK293T cells expressing HA-Rab35 and either mCh-Hrs, -STAM, -
TSG101, or –CHMP2B, immunoprecipitated (IP) with mCherry antibody and probed with HA or mCherry 
antibodies. C) Immunoblot of HEK cell lysates expressing HA-Rab35 and Flag-Hrs, incubated with either GDP or 
GTPγs, subject to IP with Flag antibody, and probed with HA and Flag antibodies. D) Quantification of HA-Rab35 
intensity normalized to Flag-Hrs intensity in the eluate and reported as a fraction of the amount in the GDP 
condition. Student’s two-tailed t-tests with a hypothetical value of 1.0 were performed (n=5; *=p<0.05). E) 
Immunoblot of HEK cell lysates expressing Flag-Hrs, subject to pull-down with GST, GST-Rab35-GDP or GST-
Rab35-GTPgs and probed with GST and Flag antibodies. F) Quantification of Flag-Hrs intensity, normalized to 
GST-Rab35 intensity in the eluate (n=4; **p<0.01).  
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Figure 4.8 - Rab35 recruits ESCRT proteins to synaptic vesicle pools. 
A) Images of neurons co-transfected with mCh-Hrs and either soluble EGFP or EGFP-Rab35, fixed and 
immunostained against VAMP2. Arrows represent mCh-Hrs puncta that colocalize with VAMP2 in axons 
expressing either soluble EGFP or EGFP-Rab35. Scale bar=10 µm. B) Images of neurons co-transfected with 
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CHMP2B-mCh and either soluble EGFP or EGFP-Rab35, fixed and immunostained against VAMP2. Arrows 
represent CHMP2B-mCh puncta that colocalize with VAMP2 in axons expressing either soluble EGFP or EGFP-
Rab35. Scale bar=10 µm. C) Quantification of the fraction of Hrs and CHMP2B puncta that colocalize with VAMP2 
in each condition (for Hrs: n=15 for control, n=19 for Rab35 from 3 replicate weeks, each with ~25 puncta/image. 
For CHMP2B: n=5 for control, n=8 for Rab35 from 2 replicate weeks, ~15 puncta/image; **=p<0.01). D) Super-
resolution images of neurons co-transfected with EGFP-Rab35 and mCh-Hrs. Inset shows higher magnification 
view of Hrs/Rab35 colocalization on an enlarged endosome created by Rab35 overexpression. E) Super-resolution 
images of neurons co-transfected with Rab35 and CHMP2B-mCh. Outline of axon is shown. Inset shows higher 




interact on endosomal membranes. In contrast, CHMP2B-mCh puncta were typically smaller and 
immediately adjacent Rab35-positive endosomes (Figure 4.8D), potentially representing a later 
stage of MVB formation. Together with our findings in HEK cells, these results indicate that  
Rab35 colocalizes precisely with the ESCRT-0 component Hrs but much less with later ESCRT 
pathway components such as CHMP2B.  
Neuronal activity stimulates Rab35 activation 
The ability of Rab35 to initiate ESCRT protein recruitment suggests that neuronal activity serves 
as a signal to activate Rab35 itself. We tested this hypothesis with an antibody that specifically 
immunoprecipitates active, GTP-bound Rab35. To verify its specificity, we co-expressed HA-
Rab35 in HEK293T cells together with soluble EGFP or EGFP-Connecdenn1, a GEF that 
activates Rab35 (Allaire et al., 2010; Marat and McPherson, 2010). Indeed, Rab35 was more 
robustly precipitated by the GTP-Rab35 antibody in lysates from cells expressing Connecdenn1 
versus soluble EGFP (Figure 4.9A). To determine if Rab35 was activated by neuronal activity, 
we next compared the levels of GTP-Rab35 in neurons treated with DMSO or Bic/4AP. 
Remarkably, we found that the GTP-Rab35 antibody precipitated nearly two times more Rab35 
from Bic/4AP-treated neurons than from control neurons (Figure 4.9B,C), suggesting that 
increased neuronal activity promotes Rab35 activation/GTP binding.  
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 Since Rab35 and Hrs interact in a GTP-dependent manner, neuronal activity should also 
enhance their binding. To test this, we immunoprecipitated mCh-Hrs from neurons treated for 12 
hours with Bic/4AP. Again, significantly more endogenous Rab35 was co-precipitated with Hrs 
following treatment with Bic/4AP versus DMSO (Figure 4.9D,E), indicating that neuronal 
activity increases the association between Rab35 and Hrs. This activity-dependent association 
likely catalyzes the recruitment of ESCRT proteins to SV pools, where they can initiate the 
formation of MVBs for SV protein degradation (Figure 4.9F).  
Discussion 
Our findings demonstrate that Rab35 mediates the use-dependent degradation of SV membrane 
proteins in mammalian neurons through the ESCRT pathway. Specifically, we find that activity 
induces the activation of Rab35, thereby promoting Hrs binding and recruitment to SV pools. 
These events in turn recruit the downstream ESCRT machinery, thereby initiating the formation 
of MVBs for delivery of specific SV proteins to lysosomes (Figure 4.9F). Together with our 
findings in chapter 3, we have identified a novel pathway that maintains SV integrity, by 
enabling neurons to replace proteins that become damaged or misfolded during SV recycling. 
Rab GTPases as coordinators of SV protein turnover 
In this chapter, we found that two Rab GTPases (Rabs 5 and 35) are capable of driving VAMP2 
and SV2 degradation. While Rab35 interacts with Hrs and specifically mediates the degradation 
of SV integral membrane proteins, Rab5 does not interact with Hrs, and stimulates the turnover 
of multiple presynaptic proteins (plasma membrane and active zone-associated), suggesting that 
it activates a broader degradative program. One possibility, based on Rab5’s link to the 
autophagic pathway (Dou et al., 2013; Ravikumar et al., 2008; Su et al., 2011), is that its 
overexpression in neurons activates macroautophagy. Indeed, previous studies have shown that 
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stimulating macroautophagy in neurons can induce the engulfment of SVs, cytoplasmic proteins, 
and other organelles by autophagosomes (Hernandez et al., 2012; Maday et al., 2014; Sanchez-
Varo et al., 2011). Interestingly, a recent study has linked the SV-associated Rab26 to the 
autophagic pathway, showing that Rab26 overexpression induces SV clustering and engulfment  
by autophagosomes (Binotti et al., 2015). Although our findings indicate that basal and activity-
dependent SV protein turnover occur through Rab35 and the ESCRT pathway, it is likely that 
specific stimuli and developmental programs (e.g. oxidative stress, protein aggregation, synapse 
elimination/pruning) can activate macroautophagy in order to degrade SVs and other synaptic 
components under certain conditions. Additional studies are needed to investigate the conditions 
under which the ESCRT pathway and macroautophagy are utilized for SV protein degradation. 
 Two other SV-associated Rab GTPases that we evaluated (Rabs 10 and 14) do not alter 
SV protein degradation, but do interact with Hrs. We hypothesize that these Rabs also participate 
in trafficking in the endolysosomal pathway, but target different classes of membrane-associated 
proteins. Gain and loss-of-function studies combined with stable isotope labeling with amino 
acids and mass spectrometry are likely to yield insights into the proteins targeted by these Rabs.  
While many of the SV-associated Rabs have been implicated in endosomal recycling in 
other cell types (Babbey et al., 2006; Junutula et al., 2004), little is known about their roles in 
neurons. We hypothesize that these may participate in the sorting process that directs SV 
proteins for reuse/recycling versus degradation. Such sorting typically occurs in early or 
recycling endosomes of non-neuronal cells, and may occur within endosomes that form 
immediately upon SV endocytosis in presynaptic boutons (Watanabe et al., 2014). Gain and loss-
of-function studies with these SV-associated Rabs, in combination with recently developed 
‘flash-and-freeze’ fixation techniques (Watanabe et al., 2014), are likely to yield insights into 
 66	  
their roles in SV protein sorting, and may help identify signals that target SV proteins for 
recycling vs. degradation.  
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Rab35 links SV protein degradation to the ESCRT pathway through its effector Hrs 
Previous studies identified Rab35 as an important regulator of the endosomal sorting and 
turnover of SV proteins (Fernandes et al., 2014; Uytterhoeven et al., 2011). Here, we provide 
mechanistic insight into how Rab35 mediates the degradation of SV proteins, by directly linking 
Rab35 to the ESCRT-0 component Hrs. The GTP-dependent Rab35/Hrs binding interaction 
implicates the ESCRT pathway as a critical mediator of SV protein degradation downstream of 
Rab35. Not only is the ESCRT pathway essential for recruiting ubiquitinated membrane proteins 
destined for degradation, but it also catalyzes the formation of MVBs to deliver this cargo to 
lysosomes. Previous work has shown that MVBs often appear in EM micrographs of presynaptic 
boutons following neuronal stimulation (Teichberg et al., 1975), suggestive of activity-dependent 
formation. Although our EM studies could not definitely show this, the concept is consistent with 
our data showing that neuronal activity stimulates protein turnover and the recruitment of 
ESCRT proteins to SV pools (Chapter 3).  
Neuronal activity 
We also provide the first example of neuronal activity as a signal for Rab GTPase activation. 
Though the GAPs and GEFs for many Rabs have been characterized (see (Barr and Lambright, 
Figure 4.9 - Neuronal activity activates Rab35 and stimulates Rab35-Hrs binding. 
A) Lysates from HEK293T cells co-transfected with HA-Rab35 and either soluble GFP or Connecdenn1-GFP, 
subject to IP with GTP-Rab35 specific antibody. Bound proteins and input were probed with HA antibody to 
detect Rab35. B) Immunoblots from 15 DIV neurons treated with DMSO or bic/4AP for 12 hours, then lysed 
and subject to IP with mouse GTP-Rab35 specific antibody and probed with rabbit Rab35 antibody. C) 
Quantification of Rab35 intensity in the eluate, normalized to input intensity and reported as a fraction of the 
DMSO control condition. Student’s two-tailed t-tests with a hypothetical value of 1.0 were performed (n=7, 
*=p<0.05). D) Immunoblots from neurons transduced with mCh-Hrs and treated with DMSO or bic/4AP for 12 
hours, then lysed and subject to IP with anti-mCherry antibody. Bound proteins and input were probed with 
Rab35 and mCherry antibodies. E) Quantification of Rab35 intensity in the eluate, normalized to input intensity 
and Hrs intensity in the eluate. Bic/4AP condition is reported as a fraction of the DMSO control condition. 
Student’s two-tailed t-tests with a hypothetical value of 1.0 were performed (n=3, *=p<0.05). F) Putative 
pathway for activity-dependent SV protein degradation. Neuronal activity (lightning bolt) serves to activate 
Rab35, which then recruits its effector, Hrs, to presynaptic endosomes. This recruitment is hypothesized to 
initiate MVB formation, leading to retrograde transport and delivery of specific SV proteins (SV2 and VAMP2) 
to somatic lysosomes for degradation. 
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2010)), few studies have addressed the signals responsible for Rab activation/inactivation. A 
recent study found that CnrF, a Rab11a GAP protein, is activated by calcium release through 
vacuolar P2XA ion channels (Parkinson et al., 2014). This signal functions to inactivate Rab11a 
in response to P2XA channel activation. Similarly, neuronal activity may induce activation or 
inactivation of Rab35 GEF or GAP proteins, respectively, thereby stabilizing Rab35 in its GTP-
bound conformation. Candidate GEFs and GAPs to regulate synaptic Rab35 activation include 
Connecdenn1, a presynaptically enriched GEF that interacts with clathrin to mediate SV 
recycling (Allaire et al., 2006), and TBC1D24/skywalker, a GAP shown to negatively regulate 
Rab35 activity in presynaptic terminals of Drosophila (Uytterhoeven et al., 2011). Whether and 
how these molecules regulate Rab35 activation in response to synaptic activity or other stimuli is 














Chapter 5 - Ubiquitination serves as a signal for VAMP2 degradation 
Rationale 
Entry of SV proteins into the degradative pathway is hypothesized to require a specific 
targeting signal. Ubiquitination is a post-translational modification that targets soluble proteins 
for degradation by the proteasome. However, its role in the degradation of integral membrane 
proteins, which are typically degraded by lysosomes, is less clear. Intriguingly, a recent study 
reported that SV membrane proteins are among the most highly ubiquitinated neuronal proteins 
(Na et al., 2012), suggesting that this modification may play an important role in their 
degradation. However, ubiquitination also regulates many non-degradative protein trafficking 
events (i.e. endocytosis, protein-protein interactions), and its role in SV protein 
trafficking/degradation is largely unexplored.  
We have determined that specific SV proteins (VAMP2 and SV2) undergo activity-
dependent degradation (Chapter 3). Given that neuronal activity has been shown to regulate 
ubiquitination (Ehlers, 2003) and to influence the protein composition of the postsynaptic density 
(Ehlers, 2003) and presynaptic active zone (Lazarevic et al., 2011), we examined whether 
ubiquitination acts as a signal for SV protein degradation. In this chapter, we demonstrate that 
ubiquitination is required for the basal and activity-dependent degradation of VAMP2. Further, 
we identify the E3 ligase, RNF167 as a major regulator of VAMP2 ubiquitination.  
Results 
Ubiquitination of VAMP2 is required for its basal and activity-dependent degradation 
In previous experiments, we found that the SV integral membrane proteins SV2 and VAMP2 
undergo activity-dependent degradation (Chapter 3). Here, we explore the function of 
ubiquitination in targeting VAMP2 to the degradative pathway. We created a ubiquitination-
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resistant version of VAMP2 by replacing its seven lysine residues with arginine (KR VAMP2; 
Figure 5.1A). We verified that KR VAMP2 localized properly to synapses, recycled with normal 
kinetics, and exhibited dramatically reduced ubiquitin immunoreactivity compared to wild-type 
VAMP2 (WT VAMP2; Figure 5.1B-D).   
 
 
Figure 5.1 - KR VAMP2 localizes to synapses and exhibits normal recycling kinetics but reduced 
ubiquitination.  A) Amino acid sequence of VAMP2 from Rattus norvegicus, showing the cytoplasmic N-terminal 
domain (shaded) and lysines (red) mutated to arginines in the KR VAMP2 construct. B) Representative images from 
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14 DIV neurons transduced with either WT VAMP2-SEP or KR VAMP2-SEP (green), and immunostained with 
synaptophysin (red) and synapsin (blue) antibodies to label SV pools. C) Sample traces of VAMP-SEP fluorescence 
from neurons transfected with WT VAMP2-SEP or KR VAMP2-SEP. D) Immunoblots of lysates from HEK293T 
cells co-expressing HA-ubiquitin and untagged WT VAMP2 or KR VAMP2, incubated for 4 hours with de-
ubiquitinating enzyme inhibitors and subject to immunoprecipitation (IP) with VAMP2 antibody followed by 
probing with HA or VAMP2 antibodies.  
 
To determine whether ubiquitination is necessary for the degradation of VAMP2, we 
transduced 7 DIV hippocampal neurons with either WT or KR VAMP2-SEP and assessed 
VAMP2 degradation using our cycloheximide-chase assay as previously described (Chapter 3). 
Interestingly, we observed a significant decrease in the degradation of KR VAMP2 compared to 
WT VAMP2 over the 24-hour time course (Figure 5.2A,B). Since we previously found VAMP2 
to undergo activity-dependent degradation (Chapter 3), we asked whether KR VAMP2 
degradation could be similarly sped with bicuculline/4AP (Bic/4AP) treatment (Chapter 3). 
Intriguingly, we found that while Bic/4AP significantly increased the degradation of WT 
VAMP2 compared to DMSO control, this treatment did not alter the degradation of KR VAMP2 
(Figure 5.2C,D), suggesting that ubiquitination of VAMP2 is necessary for both its basal and 
activity-dependent degradation. Moreover, we noticed that the steady-state levels of KR VAMP2 
were significantly higher than those of WT VAMP2 (Figure 5.2A,C), consistent with its lack of 
degradation and build-up over time. The functional effects of this KR VAMP2 build-up will be 
investigated in future experiments.  
K63-linked poly-ubiquitination of VAMP2 is required for its degradation 
We next tested which type of ubiquitination was required for VAMP2 degradation. While K48 
poly-ubiquitination serves as a signal for proteasomal degradation, multi-mono-ubiquitination 
and/or K63 linkages serve as the signal for ESCRT-mediated degradation. Since we found the 




Figure 5.2 - Ubiquitination is required for basal and activity-driven degradation of VAMP2. 
A) Immunoblots from 14 DIV neurons transduced with either WT or KR VAMP2-SEP, treated for 24 hours with 
DMSO (c) or chx and probed for VAMP2 and tubulin. B) Quantification of the fold change in degradation of 
VAMP2 for each condition (n=4, *=p<0.05). C) Representative immunoblots from 14 DIV neurons expressing 
WT or KR VAMP2-SEP, treated for 24 hours with DMSO (c) or chx in the presence of additional DMSO or 
Bic/4AP to stimulate neuronal activity, and probed for the same proteins as in A. D) Quantification of protein 
degradation in each condition, expressed as the fold change versus DMSO control (n=6, *=p<0.05). E) 
Representative immunoblots from 14 DIV neurons transduced with mCh-WT, K48R, K63R, or K0 ubiquitin 
treated for 24 hours with DMSO (c) or chx and probed for VAMP2 and tubulin. F) Quantification of the fold 
change in degradation of VAMP2 for each condition (n=7-14, *=p<0.05). 
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we hypothesized that multi-mono- or K63-ubiquitination would be required for VAMP2 
degradation. To test this prediction, we transduced neurons with ubiquitin constructs containing  
K to R mutations that render them incapable of forming specific ubiquitin linkages. We 
compared the degradation of VAMP2 in the presence of wild-type ubiquitin (Ub-WT) vs. K48R, 
K63R, and K0 (in which all lysines are mutated to arginine such that only mono or multi-mono-
ubiquitin linkages can form) ubiquitin mutants. Specifically, 10 DIV neurons were transduced 
with Ub-WT, Ub-K48R, Ub-K63R, or Ub-K0. On 14 DIV, neurons were treated with 
cycloheximide for 24 hours, then collected and subjected to immunoblotting against VAMP2.  
The expression of Ub-K48R did not significantly alter VAMP2 degradation compared to Ub-WT, 
while that of Ub-K63R and Ub-K0 significantly impaired VAMP2 degradation, suggesting the 
VAMP2 requires lysine-63 linked poly-ubiquitination for its degradation (Figure 5.2E,F).  
Ubiquitination of VAMP2 is required for its degradation by Rab35 
Our findings show that Rab35 is sufficient to drive VAMP2 degradation, and necessary for the 
basal and activity-dependent degradation of VAMP2. Therefore, we next asked if ubiquitination 
of VAMP2 is an important signal in the Rab35 pathway. For these experiments, neurons were 
co-transduced with mCh-Rab35 and either WT or KR VAMP2-SEP. As before, 24-hour 
cycloheximide treatment was used to measure the degradation of these proteins by both 
quantitative immunoblotting and immunofluorescence microscopy. Consistent with the role of 
ubiquitination as a degradative signal, we found that KR VAMP2 was resistant to Rab35-
mediated degradation, exhibiting significantly less degradation than WT VAMP2 based on 
quantitative immunoblotting, and significantly greater intensity in axons by quantitative 
immunofluorescence (Figure 5.3A-D). These data suggest that ubiquitination is an important 
signal for SV protein degradation via the Rab35 pathway.  
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Figure 5.3 - Ubiquitination of VAMP2 is required for its Rab35-mediated degradation.  
A) Immunoblots from 14 DIV neurons transduced with mCh-Rab35 and either SEP-WT or KR VAMP2, treated for 
24 hours with DMSO (c) or chx and probed for VAMP2 and tubulin. B) Quantification of VAMP2 intensity in each 
condition, expressed as the fold change versus DMSO control (n=5, *=p<0.05). C) Images from 14 DIV neurons 
transduced with mCh-Rab35 and either SEP-WT or KR VAMP2, then fixed 24 hours after chx treatment. Arrows 
represent VAMP2 puncta (green) in axons expressing Rab35 (purple), scale bar=10 µm. D) Quantification of the 
average fluorescence intensity of VAMP2 puncta, normalized to WT condition (2 replicate weeks, each with 3 
images/condition, ~75 puncta/image, n=6, **=p<0.01).  
 
RNF167 ubiquitinates VAMP2  
Given the importance of ubiquitination for VAMP2 degradation, we next wanted to identify the 
specific enzymes responsible for ubiquitinating VAMP2. A series of E1, E2, and E3 enzymes are 
required to carry out the ubiquitination of target proteins. It was previously shown that another 
VAMP, VAMP3, was ubiquitinated by the RING domain ligase Goliath/RNF167 in Drosophila  
(Yamazaki et al., 2013). The lysine residues of VAMP3 are highly homologous to those of 
VAMP2 (Figure 5.4A), suggesting that RNF167 may also function in the ubiquitination of 
VAMP2. To test if RNF167 is capable of ubiquitinating VAMP2, we performed ubiquitination 
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assays in HEK293T cells expressing soluble-mCh or mCh-RNF167 along with HA-Ubiquitin 
and VAMP2. Significantly more HA-ubiquitin immunoreactivity was detected in VAMP2 
immunoprecipitated from cells expressing RNF167 compared to soluble-mCh (Figure 5.4B,C), 
demonstrating that RNF167 can function as an E3 ligase for VAMP2.   
RNF167 is necessary for the degradation of VAMP2 
We next sought to determine if RNF167 is necessary for the ubiquitination and degradation of 
VAMP2 in neurons. To do so, we designed an shRNA against RNF167 (shRNF167) that led to 
an 80% reduction in RNF167 mRNA levels when expressed between 3-14 DIV (Figure 5.4 D). 
We subsequently used quantitative immunofluorescence microscopy to examine the degradation 
of VAMP2 in neurons expressing shRNF167. Specifically, 14 DIV neurons expressing soluble-
EGFP or shRNF167 were treated with DMSO or cycloheximide for 24 hours, fixed, and 
immunostained for VAMP2. Average fluorescence intensities of VAMP2 puncta in axons 
expressing soluble-EGFP or shRNF167 were quantified and presented as a fraction of the 
average intensity in DMSO treated controls. We found that VAMP2 levels were increased by 
25% in axons expressing shRNF167 compared to those expressing soluble-EGFP (Figure 
5.4E,F), indicating that RNF167 is necessary for VAMP2 degradation.  
Discussion 
In this chapter, we show that ubiquitination of VAMP2 is necessary for its basal and activity-
dependent degradation. Further, we identify the E3 ligase RNF167 as a ubiquitinating enzyme 
necessary for the degradation of VAMP2. These studies suggest that activity-dependent 
ubiquitination of VAMP2 is required for its degradation, though more work is needed to clarify 





Figure 5.4 - RNF167 ubiquitinates VAMP2 and is necessary for its degradation.  
A) Amino acid sequences of VAMP2 and VAMP3 from Rattus norvegicus. Lysine residues are shown in red with 
those demonstrated to be ubiquitinated by RNF167 underlined. B) Immunoblot of HEK cell lysates expressing either 
soluble-mCh or mCh-RNF167, HA-ubiquitin and untagged VAMP2, subject to IP with VAMP2 antibody and 
probed with HA or VAMP2 antibodies. C) Quantification of HA-ubiquitin intensity in the eluate, normalized to 
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VAMP2 intensity in the eluate (n=3, **p<0.01). D) Quantification of mRNA levels from 14 DIV neurons 
expressing soluble-EGFP or EGFP-shRNF167 determined by qPCR with primers to RNF167, GAPDH, and actin 
(n=3, **p<0.01). E) Images from 14 DIV neurons transduced with either soluble-EGFP or EGFP/shRNF167, fixed 
24 hours after chx treatment, and immunostained against VAMP2. Arrows represent VAMP2 puncta (purple) in 
axons expressing EGFP +/- shRNA (green). Scale bar=10 µm. F) Quantification of the fluorescence intensity of 
VAMP2 puncta, normalized to soluble-EGFP control condition (6 replicate weeks, each with 2-3 images/condition, 
~250 puncta/image, n=6, *=p<0.05).  
 
Ubiquitination as a signal for SV protein degradation 
SV membrane proteins are reported to be highly ubiquitinated (Na et al., 2012), although the role 
of ubiquitination in their trafficking and turnover has not been explored. Our study is the first to 
demonstrate that ubiquitination serves as a signal for SV membrane protein degradation, as 
ubiquitin-resistant KR VAMP2 cannot be efficiently degraded (Figure 5.2A,B). Previous studies 
have shown that artificially ubiquitinated VAMP2 (Ub-VAMP2) binds to Hrs and is a substrate 
for ESCRT-dependent degradation (Takahashi et al., 2015; Uytterhoeven et al., 2011). Since our 
previous data (Chapter 3) also demonstrate that SV protein degradation is ESCRT-dependent, we 
hypothesize that ubiquitination is a signal for the recognition of SV membrane proteins by 
ubiquitin-binding components of the ESCRT pathway. Most studies indicate that multi-mono-
ubiquitination and/or K63 linkages serve as the signal for ESCRT-mediated degradation, but this 
is an ongoing area of investigation (see (Shields and Piper, 2011)). Our results show that lysine-
63 linked poly-ubiquitination is necessary for VAMP2 degradation (Figure 5.2E-F). Given the 
high prevalence of ubiquitinated SV proteins in neurons, it is conceivable that different ubiquitin 
linkages mediate different protein trafficking events, in addition to protein degradation. Indeed, 
more work is needed to determine the potential roles of other ubiquitin linkages in SV protein 
trafficking.   
RNF167 is an E3 ligase for VAMP2 
Although we find that RNF167 is necessary for the degradation of VAMP2, more work is needed 
to determine if RNF167-mediated ubiquitination of VAMP2 lies upstream of the Rab35/ESCRT 
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pathway for degradation. Future studies will examine whether RNF167 is necessary for the 
activity-dependent degradation of VAMP2 using methods analogous to those used in Chapters 3 
& 4. Briefly, we will treat shRNF167-transduced neurons with Bic/4AP to increase neuronal 
activity, and examine whether activity-dependent VAMP2 degradation is attenuated. Further, we 
will examine whether VAMP2 ubiquitination levels increase following neuronal activity. An 
intriguing possibility is that VAMP2 accumulates ubiquitin moieties through cycles of exo- and 
endocytosis, and that these cumulative linkages target VAMP2 and other heavily-used SV 
proteins for degradation. This mechanism could function to counteract any misfolding or damage 
accrued by proteins during rounds of SV cycling. Indeed, we have observed that long-term 
expression of KR VAMP2 leads to neuronal toxicity, suggesting that KR VAMP2 accumulates 
over time and potentially become damaged/misfolded in a way that compromises neuronal health. 
Additionally, this finding suggests that the build-up of excess protein and subsequent disruption 
of protein homeostasis is deleterious to neuronal health. These topics will be explored in future 
studies to more thoroughly understand the mechanisms behind VAMP2 ubiquitination and the 










Chapter 6 - General Discussion and Future Directions 
Our findings demonstrate that Rab35 and the ESCRT machinery are essential components of the 
pathway for use-dependent turnover of SV2 and VAMP2 in mammalian neurons. Additionally, 
we find that RNF167-mediated ubiquitination is essential for the degradation of VAMP2. While 
previous studies have linked Rab35 and the ESCRT pathway to SV protein recycling and 
turnover in Drosophila (Fernandes et al., 2014; Uytterhoeven et al., 2011), our study is the first 
to demonstrate a direct mechanistic link between Rab35 and the ESCRT pathway through Hrs, 
and the first to show that turnover of specific SV proteins is regulated by neuronal activity in a 
Rab35- and ESCRT-dependent manner. Specifically, we find that activity induces the activation 
of Rab35, thereby promoting its binding to Hrs and the localization of Hrs to SV pools. These 
events in turn recruit the downstream ESCRT machinery to presynaptic boutons, and are 
hypothesized to catalyze the formation of MVBs for delivery of ubiquitinated SV proteins to 
lysosomes. Furthermore, our study is the first to establish a role for RNF167-mediated 
ubiquitination in the degradation of VAMP2. Together, our studies identify a novel pathway that 
maintains SV integrity and presynaptic fitness, by enabling neurons to replace proteins that 
become damaged or misfolded during repeated cycles of SV exo/endocytosis. 
Mechanisms of SV protein turnover   
Although several studies have examined the mechanisms of SV protein degradation, many 
outstanding questions remain regarding this process. For instance, it is currently not known 
whether SV protein turnover is stochastic, with some constant number of proteins being 
degraded at any given moment, or specific, with particular proteins singled out for degradation 
based upon their age or conformational state. A previous study in Drosophila examined this 
question by investigating the turnover of young versus old VAMP2 using fluorescent timer 
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proteins that change from blue to red emission over time (Fernandes et al., 2014; Subach et al., 
2009). In this study, older VAMP2 proteins were found to be preferentially degraded. Together 
with our findings that ubiquitination of VAMP2 is necessary for its degradation, these data 
support the idea that SV turnover is not stochastic, but rather that specific proteins are sorted out 
of the SV cycle and sent for degradation.  
Use-dependent turnover of SV proteins 
One of the most intriguing aspects of the Rab35/ESCRT degradative pathway is its regulation by 
neuronal activity. Not only are our studies the first to directly link neuronal activity to SV protein 
turnover, but they are also the first to link it to activation of a Rab GTPase. While we find that 
SV2 and VAMP2 undergo activity-dependent degradation, the degradation of Syt1 is unaffected 
by changes in activity levels (Chapter 3). Though we currently do not understand the 
mechanisms controlling this differential degradation, an interesting possibility is that different 
regulatory proteins (i.e. E3 ligases, Rab GTPases and/or chaperones) respond to certain stimuli 
and affect the stability of specific proteins. Indeed, we find that multiple Rab GTPases bind to 
Hrs, but do not affect SV2 and VAMP2 degradation (Chapter 4). These data suggest that while 
Rab35 is activated by neuronal activity to drive SV2 and VAMP2 degradation, other Rabs may 
be activated by different cues to regulate the degradation of other SV proteins. Indeed, it will be 
interesting to examine the degradation of other SV proteins in the presence of these Rabs to form 
a more comprehensive picture of the Rab-mediated regulation of SV protein degradation. 
Additionally, with the increasing development of GTP-bound, conformation specific Rab 
antibodies, it will be possible to test how different stimuli affect the activation of various Rab 
proteins.  
Roles of ubiquitination at the synapse 
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We are just beginning to understand the mechanisms underlying SV protein ubiquitination. 
Several groups have shown that postsynaptic proteins are ubiquitinated and degraded in an 
activity-dependent manner (Ehlers, 2003; Lussier et al., 2011; Schwarz et al., 2010), and that 
ubiquitinating enzymes themselves are regulated by activity (Scudder et al., 2014), providing a 
mechanism for coupling neuronal activity with postsynaptic protein ubiquitination and 
degradation. In contrast, very few studies have explored the relationship between activity and 
presynaptic protein ubiquitination, although it has been reported that silencing neurons leads to 
the accumulation of SV and other presynaptic proteins (Lazarevic et al., 2011). One intriguing 
possibility is that ubiquitinating enzymes are activated or recruited to SV pools upon neuronal 
activity. We will examine this possibility in future studies assessing the role of RNF167 in the 
activity-dependent turnover of VAMP2. As we have shown that ubiquitination of VAMP2 is 
necessary for its activity-dependent degradation, we hypothesize that RNF167 is a critical 
component of this process. First, we will determine whether RNF167 is a necessary component 
of the activity-dependent turnover of VAMP2. As discussed in Chapter 5, we will use similar 
methods to our studies with Hrs and Rab35 in this process (Chapters 3 & 4). Further, we will 
examine whether RNF167 undergoes activity-dependent recruitment to synapses through live 
imaging and immunofluorescence microscopy. Specifically, we will examine whether the 
colocalization of RNF167 with VAMP2 is induced by increases in neuronal activity analogous to 
our studies with ESCRT proteins in Chapter 3. Additionally, it will be interesting to determine if 
RNF167 also functions as an E3 ligase for SV2 or other SV proteins, and if ubiquitination is a 
general mechanism for basal and activity-dependent degradation of SV membrane proteins.  
Ubiquitin moieties can be attached to proteins singly or as poly-ubiquitin linkages built 
upon specific lysine residues (i.e. K6, K11, K29, K48, K63); thus, it is likely that synaptic 
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proteins can be modified by ubiquitination for a variety of reasons. Indeed, an assortment of 
ubiquitination events can be detected on the same protein (Bhat et al., 2014; Nonaka et al., 2005), 
suggesting that not only does the ubiquitination of these proteins affect their function but also 
that differential ubiquitination of the same protein may produce distinct functional outcomes. For 
example, studies have shown a role for dynamic ubiquitination in processes such as 
neurotransmission (Chen et al., 2003; Rinetti and Schweizer, 2010). Specifically, Rinetti & 
Schweizer found that application of the E1 activating enzyme inhibitor Ziram for as little as ten 
minutes led to an increase in the frequency of miniature excitatory postsynaptic currents. No 
protein accumulation was seen within this time frame, suggesting that the changes observed were 
not due to protein build-up, but instead to alterations in the dynamic ubiquitination state of 
presynaptic proteins. Since we are only just beginning to unravel the intricacies of the various 
roles of ubiquitination in presynaptic function, this will be an interesting and important subject 
for future investigations.  
A role for endosomal sorting in SV protein degradation 
Our findings contribute to the large body of evidence that SVs use synaptic endosomes as sorting 
stations to remove specific proteins from the SV cycle. We provide evidence that endosomes are 
important not only under high activity conditions, but also in the basal degradation of specific 
SV proteins (Chapter 3). Though we implicate the recruitment of both early and late components 
of the ESCRT pathway to SV pools, our findings cannot definitely conclude that MVB formation 
occurs within the presynaptic compartment. Future studies employing electron microscopy with 
more specific MVB labeling will be necessary to discern the exact localization of MVB 
formation in axons. 
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 Additionally, we have begun to explore ESCRT protein dynamics in axons under both 
basal and high-activity conditions. Our preliminary studies show that the velocity of Hrs puncta 
increases dramatically in response to neuronal activity; however, much is left to explore 
regarding ESCRT protein and SV protein dynamics. For instance, it will be interesting to observe 
the dynamics of other ESCRT proteins and determine whether their dynamics also change in 
response to activity. Additionally, it will be interesting to determine the necessity of Rab35 in 
activity-dependent ESCRT protein trafficking. We have also begun to explore the dynamics of 
SV proteins in response to activity, and are interested in determining whether ubiquitination is 
required for the transport of VAMP2 out of synapses.  
SV protein homeostasis and neurodegeneration 
An inability to maintain SV protein homeostasis is implicated as a causative factor in 
neurodegenerative diseases. Indeed, the accumulation of damaged or misfolded SV-associated 
proteins can induce neurodegeneration in animal models and humans (Burgoyne and Morgan, 
2015; Peng et al., 2013; Rozas et al., 2012; Sharma et al., 2012a; Sharma et al., 2012b; 
Williamson and Neale, 1998). Moreover, SV loss occurs in mouse models of neurodegenerative 
diseases, including Alzheimer’s, Parkinson’s, and lysosomal storage disorder, often prior to the 
emergence of other phenotypes (Esposito et al., 2012; Sanchez-Varo et al., 2011; Scott et al., 
2010; Virmani et al., 2005). These findings suggest that maintaining functional SV pools is 
critical for synaptic and neuronal health, and that disruption of SV protein homeostasis 
mechanisms can trigger broader neurodegenerative processes. Interestingly, loss-of-function 
mutations in TBC1D24/skywalker and the ESCRT proteins Hrs and CHMP2b cause 
neurodegeneration in mice and Drosophila as well as humans (Fernandes et al., 2014; Guven and 
Tolun, 2013; Lee et al., 2007; Lee et al., 2009; Tamai et al., 2008), implicating this highly 
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conserved pathway in the etiology of neurodegenerative disease. While TBC1D24/skywalker 
mutations promote Rab35 over-activation and SV protein degradation, ESCRT mutations impair 
this process, leading to the accumulation of ubiquitinated proteins and degradative structures 
(Fernandes et al., 2014; Guven and Tolun, 2013; Lee et al., 2007; Lee et al., 2009; Tamai et al., 
2008). Additionally, it was recently discovered that mice expressing artificially ubiquitinated 
VAMP2 (Ub-VAMP2) develop progressive degeneration of nerve terminals with obvious loss of 
SV density and the accumulation of tubulovesicular structures (Liu et al., 2015). Furthermore, in 
preliminary studies we observe toxicity with long-term expression of KR VAMP2. Our future 
work will characterize the nature of this toxicity to determine whether the lack of degradation of 
KR VAMP2 inhibits lysosomal function or interferes with the turnover of other SV proteins. All 
together, these intriguing findings suggest that both the exuberant, unregulated degradation of 
proteins and the accumulation of dysfunctional proteins are harmful to neurons. Thus, further 
study of SV protein ubiquitination and the Rab35/ESCRT pathway will not only provide insight 
into how SV protein turnover and homeostasis are regulated, but will also facilitate the 
identification of factors that promote or inhibit protein degradation, and could therefore serve as 
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